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1 Introduction 
1.1 Microglia 
The central nervous system (CNS) consists of two main cell types: neurons and glial 
cells. Neurons constitute about half the volume of the CNS and glial cells make up the 
rest. Glial cells provide support and protection for neurons. They are thus known as the 
"supporting cells" of the nervous system. The four main functions of glial cells are: (1) 
to surround neurons and hold them in place, (2) to supply nutrients and oxygen to 
neurons, (3) to insulate one neuron from another, and (4) to destroy and remove debris 
of dead neurons. In the vertebrate CNS, glial cells are divided into two major classes: 
microglia and macroglia. Commonly, astrocytes and oligodendrocytes are referred as 
macroglia.  
Astrocytes are a subtype of glial cells and characteristically star-shaped. They perform 
many functions, including the formation of the blood-brain barrier, the provision of 
nutrients to the nervous tissue, and they play a principal role in the repair and scarring 
process in the brain. Therefore, astrocytes exhibit mainly a supportive function in the 
CNS.  
In contrast, the main function of oligodendrocytes is the myelination of axons 
exclusively in the CNS of higher vertebrates, a function performed by Schwann cells in 
the peripheral nervous system. Each oligodendrocyte can wrap numerous axons, and 
each axon is ensheathed by periodically spaced processes extending from multiple 
oligodendrocytes. Rapid conduction of nerve impulses in vertebrates requires that most 
large-diameter axons be wrapped by myelin. When oligodendrocytes are damaged and 
myelin is disrupted, the neurons cannot communicate resulting in paralysis or motor 
dysfunction. 
Microglia are currently accepted as immune cells in the CNS that respond to injury and 
brain disease. The main function of microglia is believed to be brain defense, as they are 
known to scavenge invading microorganisms and dead cells, and also to act as immune 
cells. However, microglia are also thought to contribute to the onset of or to exacerbate 
neuronal degeneration as well as inflammation in many brain diseases by producing 
deleterious factors including superoxide anions, nitric oxide and inflammatory 
cytokines. Nonetheless, there is accumulating evidence that microglia produce 
neurotrophic and/or neuroprotective molecules; in particular, it has been suggested that 
they promote neuronal survival in cases of brain injury. The fact that microglia act like 
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a ‘double-edged sword’, either in a neurotoxic or in a neuroprotective way, has gained 
much recent attention. 
 
1.1.1 Origin of microglia 
In 1913, Santiago Ramón y Cajal described the ‘third element’ of the nervous system, a 
cell population distinct from neurons and neuroglia (otherwise termed astroglia). 
Microglia make up one-fifth of the CNS glial population and are believed to be of 
mesodermal origin as it was originally suggested. However, the origin of microglia 
remains still a matter of intense debate (Chan et al., 2007). For a long time, mainly due 
to the lack of cell type specific markers, the origin of microglia was unclear. In the 
1980s, cell staining techniques assumed the myeloid origin of microglia, whereas 
macroglia and neurons arise from neuroectoderm. However, there was never the formal 
proof that microglia cannot arise from the neuroectodermal lineage as well. 
Microglia are widely regarded as the resident mononuclear phagocytes of the nervous 
system. Apart from the lack of concrete evidence, nowadays, there is good evidence that 
two types of microglia coexist within the brain. First, it is assumed that resident 
microglia, which are derived from the mesoderm, colonize the nervous system primarily 
during embryonic and fetal development (Barron, 1995; Cuadros and Navascues, 1998). 
Second, it is believed that in the adulthood, bone marrow derived microglia are 
recruited from the blood and/or bone marrow into the CNS in response to an appropriate 
stimulus as seen under pathological conditions like in Alzheimer’s disease (Simard and 
Rivest, 2004; Priller et al., 2006; Simard et al., 2006).  
 
1.1.2 Microglial markers 
Characterization of microglial cells with regard to surface expression markers is 
difficult, as these cells share several antigens with macrophages making them 
undistinguishable to those. However, several studies using flow cytometry or classic 
immunostaining defined a profile of microglia corresponding to the following selected 
antigens: CD68
+
, CD45 low, CD11b
+
, CD11c high, MHC class II
+
, IBa1
+
 and F4/80
+
. 
The lack of a defined marker for the distinction of microglia and macrogphages is still a 
major problem in neurobiology (Guillemin and Brew, 2004).  
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Figure 1-1. Microglia in a murine mixed glial culture. A. Upon activation microglia 
change from a ramified phenotype into an reactive round-shaped cell (Kettenmann, 
2006) (modified). B. Bright field image of a murine primary cortical mixed glial culture 
stained with the microglial marker Tomato lectin (brown) and counterstained with 
hematoxylin (blue). Three of them, identified with arrows, are round-shaped microglial 
cells with a strong lectin staining (modified from Saura, 2007).  
 
1.1.3 Microglial phenotypes and motility 
Since microglia are the immune effector cells of the CNS, they exist in three distinct 
forms known as amoeboid, ramified and reactive/activated microglia, which serve 
different functional roles as outlined below (Fig.1-1). 
1.1.3.1 Amoeboid microglia 
Amoeboid microglia are associated with the developing CNS. In rats, it has been shown 
that amoeboid microglia appear late in gestation and disappear soon after birth (Ling et 
al., 1980; Dalmau et al., 1997). These cells exhibit a round cell body, possess 
pseudopodia and thin filopodia-like processes and contain numerous lysosomes 
indicating a motile phagocytic phenotype. During the post-natal period amoeboid 
microglia are believed to play a role in tissue homeostasis through the removal of 
inappropriate and unwanted axons (Innocenti et al., 1983; Marin-Teva et al., 2004; 
Stevens et al., 2007) and through the promotion of axonal migration and growth 
(Polazzi and Contestabile, 2002). Ultimately, amoeboid microglia develop long 
crenulated processes and transform into ramified microglia found in the adult CNS 
(Ling, 1979; Kaur and Ling, 1991). 
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1.1.3.2 Ramified microglia 
Ramified microglia are abundantly present in the brain parenchyma and constitute 
approximately 10-20% of the total glial cell population in the adult (Vaughan and 
Peters, 1974; Banati, 2003). These small round cells consist of numerous branching 
processes and possess little cytoplasm. In the adult brain the resident population of 
ramified microglia is maintained through local cell division (Lawson et al., 1992). 
Classically, ramified microglia were considered to be inactive under physiological 
conditions. However, it is now known that microglia exhibit pinocytotic activity and 
localized motility (Booth and Thomas, 1991; Glenn et al., 1991). In vivo two-photon 
microscopy studies in living mice showed that microglial processes are substantially 
motile, and survey their local surroundings through formation of random filopodia-like 
protrusions, extension and withdrawal of bulbous endings (Davalos et al., 2005; 
Nimmerjahn et al., 2005). Microglial processes directly contact neuronal cell bodies, 
astrocytes and blood vessels (Nimmerjahn et al., 2005). Therefore it seems likely that 
microglia monitor the well-being of brain cells and also clean the extracellular fluid in 
order to maintain central homeostasis (Booth and Thomas, 1991; Thomas, 1992; Fetler 
and Amigorena, 2005). This behavior of microglia is in agreement with a recent 
observation made for tissue macrophages, namely that their filopodia act as phagocytic 
tentacles that engulf debris and retracts them towards the cell body through a force-
driven mechanism (Kress et al., 2007).  
 
1.1.3.3 Reactive microglia 
In response to injury or pathogen invasion, quiescent ramified microglia proliferate and 
transform into active ‘brain macrophages’ also known as reactive microglia 
(Kreutzberg, 1996; Stence et al., 2001). Reactive microglia, which are involved in brain 
injury and neuroinflammation, are rod-like shaped, devoid of branching processes and 
contain numerous lysosomes and phagosomes. Under pathological conditions 
microglial cells polarize and converge their processes within hours towards the lesion 
site followed by migration towards the lesion site, where they play a neuroprotective 
role by phagocytosing damaged cells and debris (Davalos et al., 2005; Haynes et al., 
2006). Nucleotides such as adenosine triphosphate (ATP) are released by injured 
neurons and attract microglia via activation of purinoreceptors (Davalos et al., 2005; 
Introduction 
 
12 
Haynes et al., 2006). Within days after acute lesion microglia proliferate, a process that 
was termed reactive microgliosis.  
 
1.1.4 Immune function of microglia 
The brain’s immune system is different from most other organs. Neurons are fragile 
cells unable to withstand long-lasting exposure to toxic molecules released by activated 
peripheral immune cells that defend against invading microorganisms. The blood brain 
barrier prevents unlimited entry of blood-borne leukocytes into the brain parenchyma 
and protects the CNS through this mechanism from a potential damage as a 
consequence of a uncontrolled immunological response (Streit, 2002).  
Microglial cells represent the innate immunity of the CNS and are responsible for the 
first line of immune defense. To monitor the entire CNS parenchyma microglial 
processes extend over non-overlapping territories (Davalos et al., 2005; Nimmerjahn et 
al., 2005). Under even minor pathological conditions including various acute and 
chronic neurodegenerative diseases microglia are transformed into reactive microglia.  
The transformation of microglia into potentially cytotoxic cells occurs in response to 
numerous triggers, but only a few signals and their receptive structures are clearly 
identified. Known triggering signals include viral envelopes, bacterial cell wall 
components, and other infectious agents like prion proteins. In vitro, lipopolysaccharide 
(LPS), which is found in the cell wall of gram-negative bacteria and is known to be a 
TLR (Toll-like receptor) 4 ligand, serves as standard agent in mimicking infections to 
induce microglial transformation (Hanisch, 2002).  
Recently, chemotactic signals (CCL21 and nucleotides) released by dying or damaged 
neurons were identified to recruit phagocytic active microglia. Microglia were shown to 
express receptors like P2Y6 and CXCR3 that function as a sensor after injury, and 
activation of microglia by chemotactic signals leads to the removal of dying cells or 
their debris (de Jong et al., 2005; Koizumi et al., 2007). Whether apoptotic cells recruit 
microglia by the release of single or a combination of chemotactic signals remains still 
unclear.  
Subsequent to chemotactic stimuli, microglia migrate to the lesion site and often serve 
there as scavenger cells. Microglial phagocytosis is a highly coordinated process, which 
is mainly regulated by signals that microglia receive from their environment. Microglia 
express distinct types of receptors which are either involved in the phagocytosis of 
pathogenic organisms such as TLRs or scavenger receptors for clearance of apoptotic 
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cellular debris such as receptors recognizing phosphatidylserine (PtdSer) residues 
(Napoli and Neumann, 2008).  
Besides their phagocytic activity microglia have also been shown to promote 
neuroprotection by secretion of neurotrophic factors like nerve growth factor (Elkabes 
et al., 1996). In addition, microglia are proposed to play a role in protecting neurons 
against glutamate-mediated neurotoxicity. Under pathological conditions, astrocytic 
glutamate uptake is impaired and LPS-stimulated microglia upregulate the glutamate 
uptake protein GLT1 which might be involved in the clearance of excess glutamate 
(Hanisch and Kettenmann, 2007). 
Upon activation, reactive microglia have many functions similar to tissue macrophages, 
including phagocytosis, and production of cytokines, chemokines, complement 
components, matrix metalloproteinases, oxidative radicals, and nitric oxide (Benveniste 
et al., 2001) (Table 1-1).  
 
 
Table 1-1. Functional properties of microglia (Benveniste et al., 2001). 
Introduction 
 
14 
1.1.4.1 Inflammatory mediators 
Resting microglia constitutively synthesize neurotrophins, whereas cytokines are mostly 
produced upon appropriate stimulation (Elkabes et al., 1996). Signals like LPS or 
interferon # (IFN#) rapidly induce cytokine/chemokine gene transcription and effective 
release. However, initial release of certain cytokines, such as tumor necrosis factor $ 
(TNF$), has an autocrine impact on further release activities. Similarly, cytokines 
regulate the expression of cell surface molecules as a prerequisite for chemotactic 
movements and cellular interactions, including antigen presentation or induction of 
apoptosis (Hanisch, 2002). Essential cytokine systems produced by microglia include 
the IL1/IL18 (interleukin) family members, IL2/IL15, anti-inflammatory cytokines like 
TGF! (transforming growth factor) or IL10, IL6, type I and type II IFN, TNF and 
relatives, and chemokines. Some members of these systems are discussed in detail 
below. 
IL1 is a well-characterized pro-inflammatory cytokine and classically consists of a 17 
kilodalton (kDa) polypeptide existing in two distinct isoforms, IL1" and IL1!. Although 
IL1" and IL1! are encoded by separate genes sharing some sequence homology, they 
elicit similar biological actions. In addition, IL1 is a crucial microglial effector cytokine 
having a strategic position in innate defense and immune response. Cells of lymphoid 
and myeloid lineage are the main producers of IL1. The isoform IL1" is mainly cell-
associated, while the isoform IL1! is mostly found in soluble form. IL1 is released upon 
inflammation, but it also functions in cell proliferation and differentiation during CNS 
development (O'Connor and Coogan, 1999; Shaftel et al., 2008). Especially IL1! were 
shown to inhibit hippocampal synaptic transmission and long-term potentiation 
(O'Connor and Coogan, 1999). 
TGF! is an anti-inflammatory growth factor with multiple biological activities on 
proliferation, tissue development, migration, immune responses, apoptosis, and 
extracellular matrix remodeling (Blobe et al., 2000). TGF! exerts strong 
immunosuppressive effects by inhibiting expression of pro-inflammatory cytokines 
such as IL1 and TNF" in microglial cells (Benveniste et al., 2001). Most notably and 
further discussed in the following section, TGF! was recently shown to be involved in 
Alzheimer’s disease (AD) pathology.  
IFNs are a class of widely expressed cytokines and are known to have effects on cell 
growth and immunomodulation. The IFN family consists of two main classes: type I 
and type II. Type I IFNs are mainly involved in the resistance of mammalian cells 
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against viral infections and are secreted by most cells upon stimulation. In contrast, only 
certain cells of the immune system produce type II IFNs, including natural killer cells 
and T cells. IFN# is the only type II IFN and it exhibits no marked structural homology 
with type I IFN. In microglia, IFN# causes induction and upregulation of many cell 
surface molecules, namely MHC class I and II, intercellular adhesion molecules 
(ICAM-I), costimulatory molecules B7 (CD80/86), leukocyte function-associated 
molecule 1 (LFA-1), LPS receptor (CD14), Fc and complement receptors, changes in 
the proteasome composition, as well as release of cytokines, complement and nitric 
oxide (NO) (Hanisch, 2002).  
TNF$ is a pro-inflammatory cytokine that is produced by monocytes/macrophages, 
dendritic cells, or lymphocytes regulating growth and differentiation of cells. In the 
CNS, TNF$ is produced by neurons, astrocytes, and microglia. In particular microglia 
produce TNF$ that acts in an autocrine and paracrine manner to activate the population 
of immune cells across the brain parenchyma (Nadeau and Rivest, 2000). In CNS 
insults, rapid release of TNF$ by microglial cells could critically influence subsequent 
events. Upon TNF$ release, activated microglial cells and recruited immune cells from 
the periphery effectively and specifically phagocytose the initially damaged tissue. This 
early phagocytic activity may prevent subsequent secondary damages, since the absence 
of TNF$ may delay activation of microglial cells, which leads to an exaggerated and 
non-specific activation of microglia by the accumulation of necrotic debris. However, 
this microglial activation seems to be TNF$ specific, since these effects were not 
observed with other pro-inflammatory cytokines like IL1 (Blais and Rivest, 2004; 
Glezer et al., 2007).  
NO is a unique biological messenger molecule which mediates diverse physiologic 
roles. NO is involved in blood vessel relaxation, activation of macrophages and in 
neurotransmission by central and peripheral neurons. NO is produced from three NO 
synthase (NOS) isoforms: neuronal NOS (nNOS), endothelial NOS (eNOS), and 
inducible NOS (iNOS). In the CNS, NO plays important roles in the regulation of 
neurotransmitter release, neurotransmitter reuptake, neurodevelopment, synaptic 
plasticity, and regulation of gene expression. However, excessive production of NO 
following a pathologic insult leads to neurotoxicity. Microglia induce membrane-bound 
iNOS that may be important in host defense function. Moreover, after initial stimulation 
by cytokines, large amounts of NO produced by iNOS in the microglia may cause 
cellular damage. NO plays a role in mediating neurotoxicity associated with a variety of 
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neurologic disorders, including stroke, Parkinson's Disease, and HIV dementia (Dawson 
and Dawson, 1998). 
 
1.2 Alzheimer’s Disease 
Alzheimer’s disease (AD) is a neurodegenerative disorder leading to cognitive, memory 
and behavioral impairments. It is the most common form of dementia in people over 65 
years of age affecting nowadays 20 to 30 million people worldwide (Selkoe, 2005). It 
will become an increasing health problem due to extended life expectancies in 
developed countries.  
AD often begins with subtle, intermittent deficits in remembering minor events of 
everyday life, such as forgetfulness and difficulties recalling new names.  These mild 
memory deficits, primarily affecting short-term memory, gradually process to severe 
dementia and stupor. Late stage symptoms include multiple cognitive and behavioral 
spheres frequently accompanied by additional neurological symptoms such as 
extrapyramidal motor signs, slowed movements and hampered motor coordination. 
Death occurs, on average, 9 years after the initial clinical diagnosis and is usually 
caused by respiratory complications such as aspiration or pneumonia (Heneka and 
O'Banion, 2007). No cure or preventative therapy is yet available and the definitive 
diagnosis of AD is still based on post-mortem histopathological examinations of the 
patient’s brains.  
 
1.2.1 Neuropathological aspects of AD 
The pathological hallmark of AD consists of cortical atrophy with accumulation of 
extracellular deposits of amyloid ! (A!) peptide in senile plaques and intracellular 
neurofibrillary tangles (NFT) of hyperphosphorylated tau found in neurons in the 
cerebral cortex (De Strooper and Annaert, 2000).  
While the majority of AD cases are sporadic, about 5% are caused by mutations 
(familiar AD). The discovery of mutations involved in AD led to substantial progress 
with regard to possible mechanisms underlying the disease. Indeed, several mutations 
have been found in a gene encoding the amyloid precursor protein (APP). APP is a 
transmembrane protein which is known to be processed by two different cleavage 
pathways in vivo, the non-amyloidogenic and the amyloidogenic pathway (Fig.1-2). 
Usually about 90% of APP enters the non-amyloidogenic pathway, and only 10% the 
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amyloidogenic one, but these ratios may change due to mutations, environmental 
factors, as well as the age of the individual.  
In the prevalent non-plaque-forming pathway (non-amyloidogenic), APP is cleaved by 
"-secretase within the A! domain, at a position 83 amino acids away from the carboxy 
(C) terminus. A soluble extracellular fragment (sAPP") and a C-terminal fragment 
(C83) are produced. The latter can be further cleaved intramembranously by %-secretase 
to produce a small peptide termed P3. Importantly, cleavage by the "-secretase occurs 
within the A! region, thereby preventing formation of A! (LaFerla et al., 2007).  
In the amyloidogenic pathway APP is cleaved by !-secretase, leading to the generation 
of a soluble extracellular fragment (sAPP!) and a C-terminal fragment (C99) within the 
membrane. Subsequent cleavage of C99 (between residues 38 and 43) by the %-secretase 
liberates an intact hydrophobic A! peptide, which is prone to fibril formation. The %-
secretase has been identified as a complex of enzymes composed of presenilin 1 or 2, 
(PS1 and PS2), and others. Most of the full-length A! peptide produced is 40 residues 
in length (A!40), whereas a small proportion (approximately 10%) is the 42 residues 
variant (A!42). The longer and more hydrophobic A!42 is much more prone to fibril 
formation than is A!40 and even though A!42 is a minor form of A!, it is the major A!  
species found in cerebral plaques (Esler and Wolfe, 2001).  
Mutations in genes encoding the two homologous presenilins, PS1 and PS2, and !APP 
itself, have been shown to influence amyloid production and plaque formations (Haass, 
1997; Selkoe, 1998). These conditions are the K595M and N596L (Swedish) double 
APP mutation at the !-site APP-cleaving enzyme (BACE) cleavage site, and a 
duplication of a small region within the APP gene (Citron et al., 1992; Cai et al., 1993; 
Rovelet-Lecrux et al., 2006). Taken together, studies on the human genetics of AD 
points to ‘wrong’ processing of APP being directly involved in the pathology of the 
disease. However, neither the physiological function of the fragments (related or not 
related to A!) generated by the proteolysis of APP, nor the physiological function of 
APP is known at this point. 
In AD pathology two types of plaques are distinguished. First, there are neuritic plaques 
consisting primarily of neuronal processes surrounding a fibrillar A! core, and secondly 
diffuse plaques. The neuritic plaques are also the foci of local inflammatory responses, 
which are discussed in detail below. In contrast, these inflammatory responses are not 
found within diffuse plaques, which are considered as clinically benign A! deposits 
(Benveniste et al., 2001).   
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NFTs are composed of intraneuronal cytoplasmic accumulations of non-membrane-
bound bundles of paired helical filaments, consisting of hyperphosphorylated tau. Tau is 
also found in dystrophic neurites. It is present in aggregates conjugated with ubiquitin 
comparable to other aggregating intraneuronal proteins, such as $-synuclein 
predominantly found in Parkinson’s disease (Lee et al., 2001). 
 
 
Figure 1-2. APP proteolysis. The A! peptide is derived via proteolysis from a larger 
precursor molecule called the amyloid precursor protein (APP). APP can undergo 
proteolytic processing by one of two pathways (LaFerla et al., 2007). 
 
1.2.2 Transgenic mouse models of AD 
Transgenic mice expressing pathogenic mutations of human genes have become a 
powerful tool for biomedical research and drug discovery. Based on the discovery of 
familiar AD linked mutations in APP, different transgenic mouse models 
overexpressing human mutant and non-mutant APP were generated. Depending on their 
mutations these mice exhibit various phenotypes allowing the analysis of diverse 
aspects of AD related pathogenesis.  
In 1995, the first APP transgenic mouse model was described that progressively 
develops many of the pathological hallmarks of AD, including numerous extracellular 
thioflavin S-positive A! deposits, neuritic plaques, synaptic loss, astrocytosis and 
microgliosis (Games et al., 1995). Today, there are more than 40 different types of 
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APP-transgenic mice available and more than 100 transgenic mice expressing mutations 
in other genes related to AD (i.e. BACE, PS1, PS2, and tau). In 1997, Sturchler-Pierrat 
and colleagues generated another APP mouse model, the APP23 mouse. APP23 mice 
express the 751 amino acid isoform of hAPP with the Swedish mutation (K670N, 
M671L) (sweAPP) driven by the neuron specific promoter Thy1. Transgene derived 
APP levels are 7-fold higher than endogenous APP (Sturchler-Pierrat et al., 1997). 
Histopathologically, these mice are characterized by progressive A! deposition, which 
first appears at 5-6 months of age. In these mice activated microglia and astrocytes are 
associated with A! plaques, and dystrophic neurites and tau protein 
hyperphosphorylation has also been described (Sturchler-Pierrat et al., 1997). APP23 
mice show an age-dependent decline of spatial memory capacities (Kelly et al., 2003). 
Due to the fact that single transgenic mice like the APP23 do not allow the analysis of 
the full spectrum of AD like pathology, double and triple transgenic mice have been 
generated. The APP/PS1 mouse model is a double transgenic mouse expressing a 
double mutation in APP (Swedish APP mutation APPK670N, M671L and APPV717I under the 
mouse Thy-1 promoter) and a mutation in presenilin-1 (PS-1 M146L under the pHMG 
promoter), and develops large numbers of fibrillar A! deposits in cerebral cortex and 
hippocampus far earlier than their single transgenic littermates (Holcomb et al., 1998). 
In 2003, Oddo and colleagues created a triple-transgenic model (3xTg-AD) harboring 
PS1M146V, sweAPP, and tauP301L transgenes. 3xTg-AD mice progressively develop 
plaques and tangles. Prior to visible plaque and tangle pathology, synaptic dysfunction, 
including long-term potentiation deficits, are developed in an age-related manner. Both 
A!-deposition and tau-aggregates exhibit a very similar expansion pattern as described 
in AD patients (Oddo et al., 2003). Therefore, 3xTg-AD mice might reflect the 
neuropathology of AD best and became a powerful model in AD research. However, the 
simultaneous expression of three mutant proteins does not allow the investigation, how 
one of these proteins contributes to pathological effects itself.  
 
1.2.3 Neuroimmunological aspects of AD 
A! plaques and NFTs are the key pathological hallmarks in AD, but may not account 
for all clinical symptoms of AD. Epidemiological studies on the treatment of arthritis 
with anti-inflammatory agents showed that anti-inflammatory drugs may have a 
protective effect against AD. These clinical studies substantiated that the immune 
system is involved in the pathogenesis of AD (McGeer et al., 1996). Indeed, the earliest 
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clinical symptoms arise before neuronal degeneration is apparent. Nowadays, there is 
compelling evidence that cellular and molecular components of the immune system 
represent a third player in AD pathogenesis. Inflammation in AD appears only to arise 
within the CNS, with little or no involvement of lymphocytes and monocytes beyond 
their normal surveillance of the brain (Wekerle et al., 1987). How and when 
inflammation arises in the course of AD has not yet been fully resolved. Throughout the 
years, AD inflammation research has been focused on various subjects including 
cytokines, complement, chemokines, growth factors, oxidative stress, microglial 
activation, and astrocyte reactivity. However, it is important to realize that 
inflammatory reactions are highly interactive and almost never occur in isolation from 
each other. Indeed, it is still widely discussed what stimulators provoke the 
inflammatory reaction found in AD brain. 
 
1.2.3.1 Complement system in AD 
The complement system is a sophisticated system evolved to destroy pathogens and to 
assist in the phagocytosis of waste material. Four main functions are carried out by 
complement: recognition, opsonization, activation of inflammation and killing of the 
pathogen (Boche and Nicoll, 2008). Cumulative evidence suggests that A! plaques play 
a pivotal role as inducers of neuroinflammation. In vitro studies proposed that fibrillar 
A! can activate the classical complement cytolytic pathway by binding complement 
factor C1q, the first component of the C1 complex, in the absence of antibodies (Rogers 
et al., 1992). Such activated early complement factors could be responsible for the 
recruitment and activation of microglial cells expressing complement receptors like 
CR3. Studies in the late nineteen eighties demonstrated that reactive microglia are 
closely associated with neuritic and amyloid plaques, but not with diffuse plaques 
(Rozemuller et al., 1989; Sasaki et al., 1997). In AD, it is assumed that the complement 
system is strongly activated and could participate either in exacerbation or amelioration 
of the pathology. Recent studies investigating the role of the complement system in AD 
are controversial. The most recent report showed that C3-deficient APP transgenic mice 
had accelerated A! plaque deposition and neurodegeneration compared to their controls 
suggesting a beneficial role for C3 in plaque clearance (Maier et al., 2008). However, 
APP transgenic mice lacking C1q had no change in A! plaque load compared to control 
mice but showed decreased glial activation, surrounding plaques and a slowing of 
neuronal pathogenesis, suggesting a detrimental effect of C1q on neuronal activity 
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(Fonseca et al., 2004). Taken together many studies underline the hypothesis that the 
complement system is involved in the neuroinflammation found in AD. However the 
beneficial or detrimental role of the complement system is still controversial discussed. 
 
 
Figure 1-3. A!  induced immune response leading to neurotoxicity in AD (modified 
from Glezer et al., 2007). 
 
1.2.3.2 Microglia in AD 
The role of microglia in the pathogenesis of AD is not elucidated yet. Some groups have 
performed a lot of effort in trying to unravel the role of microglia in the pathogenesis of 
AD. On one hand, there is literature documenting the fact that A! serves as a potent 
microglial activator. Stimulation of microglia with A! results in the production of 
various inflammatory mediators such as IL1!, TNF", IL6, IL8, MIP (macrophage-
inflammatory protein)-1$, MCP (monocyte chemoattractant protein)-1, the complement 
component C3 and its receptor, NO and glutamate (Benveniste et al., 2001) which 
might lead to a detrimental effect in the tissue. However, there are also studies that 
show a neuroprotective role of microglia in AD. The occurrence of activated microglia 
surrounding A! plaques suggests their phagocytic attempt to remove A! plaques 
(Frautschy et al., 1998). Microglia secrete proteolytic enzymes like metalloproteinases 
that degrade A! (Qiu et al., 1997) and express receptors that are involved in the 
clearance and phagocytosis of A! and tissue debris (Napoli and Neumann, 2008).  
In a APP transgenic mouse model of AD, bone marrow-derived cells were recruited to 
senile plaques and eliminated A! plaques by a cell-specific phagocytic mechanism 
(Simard et al., 2006). Recruitment of bone marrow-derived myeloid cells to senile 
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plaques and differentiation into microglial-like cells after irradiation and bone marrow 
transplantation have also been observed by several other groups (Malm et al., 2005; 
Stalder et al., 2005). In all studies the invaded bone marrow-derived cells obtained 
morphologies and lineage markers very similar to resident microglia. However, two 
recent reports raised the question whether CNS invasion of bone marrow-derived cells 
is really a consequence of the disease process or rather induced by irradiation damage 
generally observed upon the generation of bone marrow chimeric mice (Ajami et al., 
2007; Mildner et al., 2007).  
Recently the dynamics of microglial cells in an animal model of AD was monitored by 
in vivo two-photon microscopy (Bolmont et al., 2008; Meyer-Luehmann et al., 2008). 
Plaque formation was followed by microglial activation and recruitment to the plaque 
within 1-2 days (Meyer-Luehmann et al., 2008). After microglial recruitment 
dysmorphic neurites appeared over the next days to weeks (Meyer-Luehmann et al., 
2008). The microglial cell body stayed at the plaque, while the processes showed 
permanent movements at the plaque/glia interface (Bolmont et al., 2008). The number 
of plaque-associated microglia increased at a rate of almost three per plaque per month, 
independent of plaque volume (Bolmont et al., 2008). Although the microglia appeared 
to restrict the plaque growth, it is unclear why they failed to remove the plaque by 
phagocytosis.  
The chemokine receptor CCR2, a major chemokine receptor for microglia and blood 
derived monocytes, contributed to the accumulation of these immune cells in the CNS 
of a transgenic mouse model of AD, and CCR2 deficient AD mice exhibited increased 
A! deposits in the perivascular areas of the CNS (El Khoury et al., 2007). Therefore 
some of these recruited cells might limit A! plaque load probably through phagocytosis 
and it is suggested that clearance by resident microglia seems to be limited, maybe due 
to desensitization of microglial CCR2 that renders them non-responsive to injury 
(Britschgi and Wyss-Coray, 2007).  
 
1.2.3.3 Cytokines in AD 
The major classes of cytokines are the IFNs, ILs, TNFs, and colony-stimulating factors. 
Four main cytokines have been extensively investigated in AD: IL1, IL6, TNF" and 
TGF!. Studies on cytokine production revealed that A! stimulates a NF"B-dependent 
pathway that is required for the production of cytokines (Heneka and O'Banion, 2007). 
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Increased IL1 expression in reactive microglia surrounding amyloid plaques initially 
indicated that IL1 may be associated with AD pathogenesis. Since that time, many 
groups reported on the regulation of APP processing and A! production by IL1 in vitro 
(Shaftel et al., 2008). Furthermore, A! plaques are positively stained for IL1, IL6 and 
TGF!1, and elevated TNF" and TGF!1 levels have been detected in the serum and 
cerebrospinal fluid of AD patients (Boche and Nicoll, 2008). The production of 
interleukins and other cytokines or chemokines may also lead to microglial activation, 
astrogliosis, and further secretion of pro-inflammatory molecules. However, a second 
function of cytokine action is manifested by elevated levels of inhibitory, anti-
inflammatory cytokines such as IL1 receptor antagonist (IL1Ra), IL4, IL10 and TGF!. 
In particular TGF! signaling moved into the focus of many studies. Tesseur and 
colleagues reported that the TGF! type II receptor (TGF!RII) is mainly expressed by 
neurons, and that TGF!RII levels are reduced in human AD brain and correlate with 
pathological hallmarks of the disease. In vivo, reducing neuronal TGF! signaling 
resulted in age-dependent neurodegeneration and promoted A! accumulation and 
dendritic loss in a mouse model of AD (Tesseur et al., 2006). In another recent study, 
mice lacking functional TGF! and downstream Smad2/3 signaling were crossed with 
transgenic APP mice. Aged double-transgenic mice showed complete mitigation of 
defective spatial working memory accompanied by attenuated brain parenchymal and 
cerebrovascular A! deposits and A! abundance (Town et al., 2008).  Taken together 
both studies point out that dysfunction of TGF!/TGF!RII signaling may accelerate A! 
deposition, CNS inflammation and injury suggesting that intact TGF! signaling may 
reduce neurodegeneration, thus having a beneficial role in AD immunopathology.  
 
1.3 Embryonic stem cells 
Embryogenesis is the process by which the embryo is formed and develops. It starts 
with the fertilization of the egg which has the ability to generate an entire organism. 
This capacity, defined as totipotency, is retained by early progeny of the zygote up to 
the eight-cell stage of morula. Subsequently, cell differentiation results in the formation 
of a blastocyst composed of outer trophoblast cells and undifferentiated inner cells (also 
called inner cell mass). Cells of the inner cell mass (ICM) are no longer totipotent but 
pluripotent. Pluripotent cells retain the ability to develop into all cell types of the 
embryo (Fig. 1-3) (Wobus and Boheler, 2005). 
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In 1981, Evans and Kaufman succeeded in cultivating pluripotent cell lines from mouse 
blastocysts (Evans and Kaufman, 1981). These cell lines, termed embryonic stem (ES) 
cells, originated from the ICM and could be maintained in vitro on a feeder layer of 
mouse embryonic fibroblasts (MEF) without any apparent loss of differentiation 
potential (Fig.1-4). Once established, murine ES (mES) cell lines displayed an almost 
unlimited proliferation capacity in vitro and retained the ability to contribute to all cell 
lineages. In vitro, mES cells maintained a relatively normal and stable karyotype, even 
during continuous passaging (Smith, 2001). 
Since the culture of mES cell lines initially required a monolayer of inactivated MEFs, 
it was suggested that fibroblasts supplied some important factors either to promote self-
renewal or to suppress differentiation. In 1988, two independent groups identified 
leukemia inhibitory factor (LIF) as the trophic factor responsible for both activities 
(Smith et al., 1988; Williams et al., 1988). LIF, an IL-6 class cytokine, is a soluble 
glycoprotein of myeloid origin and induces differentiation in M1 myeloid leukemia 
cells (Williams et al., 1988). Other members of the IL-6 family show similar properties, 
especially with respect to maintenance of mES cell pluripotency (Niwa et al., 1998; 
Burdon et al., 1999). The absence of IL-6 family members, the removal of MEFs, or the 
inactivation of STAT3, a downstream signaling molecule of the gp130 signaling 
complex, promote ES cells to spontaneously differentiate in vitro (Boeuf et al., 1997; 
Wobus and Boheler, 2005).  
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Figure 1-3. Stem cell hierarchy. Zygote and early division stages (blastomeres) to the 
morula stage are defined as totipotent, since they can generate a complex organism. At 
the blastocyst stage, only the cells of the ICM retain the capacity to build up all three 
primary germ layers, the endoderm, mesoderm, and ectoderm as well as germ cells, the 
founder of male and female gametes. In adult tissue, multipotent stem and progenitor 
cells exist in tissues and organs to replace lost or injured cells. At present, it is not 
known to what extent adult stem cells may also transdifferentiate into cells of other 
lineages or what factors could enhance their differentiation capability (dashed lines) 
(modified from Wobus and Boheler, 2005). 
 
Undifferentiated mES cells express specific cell surface and molecular markers that 
define the basis of stem cell identity or “stemness”. The specific cell surface antigen, 
SSEA-1 (Solter and Knowles, 1978), the membrane-bound receptor, gp130 (Niwa et al., 
1998; Burdon et al., 1999), and the enzyme activity of alkaline phophatase (Wobus et 
al., 1984), but also various signaling molecules like Oct3/4 (Scholer et al., 1989; Pesce 
et al., 1999), Nanog (Chambers et al., 2003; Mitsui et al., 2003), Rex1 (Rogers et al., 
1991; Hosler et al., 1993) or Sox2 (Avilion et al., 2003), define the stemness of mES 
cells. The ES cell property of self-renewal is therefore a balance of many signaling 
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molecules. An imbalance in any of these molecules can cause the loss of ES cell 
stemness.  
 
 
Figure 1-4. Devolopmental origin of pluripotent embryonic stem cell lines of the 
mouse. The scheme demonstrates the derivation of embryonic stem cells between 
embryonic day E2 to E3.5. Cells have been derived from the ICM of blastocysts 
(modified from Wobus and Boheler, 2005).  
 
1.3.1 In vitro differentiation potential of ES cells 
The in vitro differentiation potential of mES cells facilitated the examination of mouse 
embryogenesis. During mouse embryogenesis, three germ layers are derived from the 
primitive ectoderm of the epiblast: endoderm, mesoderm, and ectoderm. All tissues and 
organs of the developing embryo are established from these germ layers.  
Differentiation is induced by culturing ES cells as aggregates (embryoid bodies) in the 
absence of the self-renewal signals provided by feeder cells or LIF. Once differentiation 
has begun, cells representing primary germ layers spontaneously develop in vitro. First, 
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an outer layer of endoderm-like cells forms within the embryoid bodies (EBs), followed 
by the development of an ectodermal zone and subsequent specification of mesodermal 
cells. EB’s develop in suspension and their transfer to tissue culture plates allows 
continued differentiation into a range of specialized cell types (Wobus and Boheler, 
2005). 
 
1.3.1.1 Endodermal differentiation 
Pancreas and liver are derivatives of the definitive endoderm. The generation of insulin-
producing pancreatic cells from an unlimited source as ES cells is especially critical in 
the treatment of diabetes. Hepatic cells derived from ES cells show hepatic-restricted 
transcripts and proteins (Hamazaki et al., 2001; Jones et al., 2002) and can successfully 
integrate and function in a host liver upon transplantation (Chinzei et al., 2002; Choi et 
al., 2002). Due to these findings, it can be suggested that mES differentiate into all three 
lineages of the liver (hepatocytes, bile duct epithelial and oval cells). In terms of 
pancreatic differentiation, the capacity of mES seems to be more restricted. In vitro, 
spontaneous differentiation of mES cells into insulin-producing pancreatic endocrine 
cells results in only a small fraction (% 0.1%) (Shiroi et al., 2002). Initially, the first 
successful induction of pancreatic differentiation of ES cells was obtained by stable 
transfection with a vector expressing a neomycin-resistance gene under the control of 
the insulin promoter. This enabled lineage selection and maturation of insulin-
expressing cells which resulted in the normalization of glycemia in streptozotocin-
induced diabetic mice (Soria et al., 2000). Different modification of the protocol 
allowed the generation of insulin-producing clusters from ES cells, but further 
improvements are necessary for the transplantation of functional cells.  
1.3.1.2 Mesodermal differentiation 
Mesoderm is the germ layer that develops into muscle, bone, cartilage, blood, and 
connective tissue. Around embryonic day E6.5, blood and endothelial cells are among 
the first differentiated mesodermal cell types. In these days, the yolk sac, an 
extraembryonic membrane composed of adjacent mesodermal and primitive (visceral) 
endodermal cell layers, is formed. The yolk sac gives rise to blood and endothelial cells 
(Baron, 2001). Hematopoietic cells and blood vessels are believed to arise from a 
common progenitor cell, the “hemangioblast”. mES cells have been successfully used to 
recapitulate these mesodermal developmental processes in vitro. Differentiation of ES 
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cells in complex cystic EB’s permits the generation of blood islands containing 
erythrocytes and macrophages (Doetschman et al., 1985), whereas differentiation in 
semisolid medium is efficient for the formation of neutrophils, mast cells, macrophages, 
and erythroid lineages (Wiles and Keller, 1991). Application of FCS and cytokines such 
as IL-3, IL-1, and granulocyte-macrophage colony stimulating factor (GM-CSF) to ES 
cells generates early hematopoietic precursor cells. The development of all 
hematopoietic cell types of the erythroid, myeloid, and lymphoid lineages (Nakano et 
al., 1994) and of natural killer cells was achieved using OP9 cells (Hole, 1999; Wobus 
and Boheler, 2005). Most of the cellular phenotypes of ES derived hematopoietic cells 
have been characterized by specific gene expression patterns and by cell surface 
antigens (Wiles and Keller, 1991; Wang et al., 1992). However the most important issue 
of these cells is functionality. Differentiated cells must show long-term multilineage 
hematopoietic repopulating properties to be considered true hematopoietic stem cells. 
Initially, it was reported that the repopulating ability of ES cell derived hematopoietic 
progenitors may be restricted to the lymphoid system (Muller and Dzierzak, 1993), but 
subsequent studies showed a long-term multilineage hematopoietic repopulating 
potential of ES derived cells (Palacios et al., 1995; Hole et al., 1996). 
Besides hematopoetic lineage commitment, mES cells efficiently differentiate into 
several other mesodermal cell types, including adipogenic (Dani et al., 1997), 
chondrogenic (Kramer et al., 2000), osteoblast (Buttery et al., 2001), and myogenic 
(Rohwedel et al., 1994) cells.  
1.3.1.3 Ectodermal differentiation 
The neuroectodermal lineage gives rise to the peripheral and CNS and to the epithelial 
lineage, which is committed to becoming epidermal tissue. Epithelial cell differentiation 
from ES cells displays morphological patterns similar to normal embryonic skin. 
Compared to native skin, the cells express late differentiation markers of epidermis and 
markers of fibroblasts which suggest that ES cells have the capacity to reconstitute in 
vitro fully differentiated skin (Coraux et al., 2003). Neuronal and glial differentiation of 
ES cells became of specific importance with respect to cell based therapies of 
neurodegenerative disorders. In 1995, three independent groups showed the neuronal 
differentiation of mES cells (Bain et al., 1995; Fraichard et al., 1995; Strubing et al., 
1995). Different strategies were used to improve the differentiation of ES cells to 
neurons, involving the use of retinoic acid (RA) (Rohwedel et al., 1999), lineage 
selection (Li et al., 1998; Ying et al., 2003), and stromal cell-derived inducing activity 
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(Kawasaki et al., 2000). Since RA is a teratogenic compound alternative protocols have 
been established which involve multiple steps of differentiation and selection of neural 
progenitors. In this protocol, EBs are generated, and subsequently cells are cultured in 
serum-free conditions to inhibit mesodermal differentiation. The proliferation of neural 
precursors is then induced by the supplementation of bFGF (basic fibroblast growth 
factor) and EGF (epidermal growth factor). The withdrawal of these factors induces the 
final differentiation of neurons (Okabe et al., 1996), (Lee et al., 2000). Gene expression 
and electrophysiological studies of cell derivatives indicate the presence of all three 
major cell types of the brain: neurons [dopaminergic and serotonergic (Lee et al., 2000), 
GABAergic and glutamatergic (Finley et al., 1996) and cholinergic (Fraichard et al., 
1995) neurons], astrocytes and oligodendrocytes (Brustle et al., 1999). 
Microglia, as already discussed, are believed to origin from the mesoderm, although a 
contribution from the neuroectoderm can so far not completely excluded. It is assumed 
that microglial precursor invade the CNS from the yolk sac during embryonic days. 
Thus, differentiation of mES cells into microglial-like cells was described the first time 
during a differentiation protocol that normally generates dopaminergic neurons (Lee et 
al., 2000). In 2005, Tsuchiya and colleagues showed the first time the induction of a 
large number of mature microglial-like cells from mES. During neuronal differentiation 
they found a population positively stained for IBa1
+
 and CD45
+
, which are common 
microglial markers, and isolated those cells with a gradient method. After intravenous 
application of GFP
+
 ES cell derived microglial-like cells, they showed microglial 
migration into the brain parenchyma and detected GFP
+
 cells in the corpus callosum, 
hippocampus and cerebral cortex, but not in other peripheral organs (Tsuchiya et al., 
2005).  
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1.4 Aims of the study 
Microglia are resident immune cells of the CNS. They are involved in the homeostasis 
of the healthy CNS, but they are also found to be involved in many pathological 
conditions of the CNS. In experimental research, primary microglia are directly isolated 
from the brain or from mixed glial cultures derived from early postnatal brain tissue, 
however isolation of primary microglia is time consumable and inefficient due to low 
cell yield. Alternatively, the microglia-derived oncogenically transformed cell line BV2 
is used as substitute for primary microglia, but many studies showed that BV2 cells are 
limited in several microglial functions and are therefore not suitable as replacement for 
primary microglia.  
Therefore, the first aim of this study is to establish a standard protocol for the 
differentiation of mES cells into microglial (precursors) cell lines. These lines are 
characterized according to their immunological and functional properties in vitro as well 
as in vivo and compared to primary microglia.  
The role of microglia in AD is still under investigation. Some findings point to a 
protective role of microglia and discuss their diminished phagocytosis of A! as a key 
element in the pathogenesis of AD. According to that hypothesis, we aim to use ES cell 
derived microglia precursors as a tool in a therapy approach in a mouse model of AD. 
For that reason, ES cell derived microglial precursors are genetically modified using 
lentiviral technology. ES cell derived microglial precursors overexpressing GFP under a 
ubiquitous promoter are injected locally to APP transgenic mice (APP23) to observe 
their impact on plaque size and distribution.   
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2 Materials and Methods 
2.1 Materials 
2.1.1 Buffers and solutions 
• 10X (0.125M) Phosphate buffered saline (PBS), pH 7.3 
Components Concentration Company 
NaH2PO4*H2O 0.007M Roth, Germany 
NaH2PO4*7H2O 0.034M Roth, Germany 
NaCl 0.6M Roth, Germany 
ddH2O up to 1 liter Roth, Germany 
 
• 4% Paraformaldehyd (PFA), pH 7.3  
Components Amount Company 
PFA 20g Sigma, Germany 
NaOH 30ml Roth, Germany 
PBS (10X) 50ml  
ddH2O up to 1 liter Roth, Germany 
 
• 10X TBE buffer 
Components Concentration Company 
Tris-Base 1.78M Roth, Germany 
Boric Acid 1.78M Sigma, Germany 
EDTA 0.04M Roth, Germany 
ddH2O up to 2 liter Roth, Germany 
 
Materials and Methods 
 
32 
• 6X Loading buffer 
Components Concentration Company 
EDTA 0.5M Roth, Germany 
Sucrose 60% Roth, Germany 
Bromphenol Blue 0.04% Sigma, Germany 
Xylene Cyanole 0.04% Sigma, Germany 
Ficol-400 2% Bio-Rad, Germany 
 
• 1% Agarose gel  
Components Amount Company 
Agarose 0.5g Biozym, Germany 
Ethidium Bromide 1.25#l Roth, Germany 
TBE (1X) 50ml  
 
• Reverse transcription (RT) mix  
Components Amount Company 
Total RNA 5#g  
Hexanucleotide Mix (10X) 1#l Roche, Germany 
dNTP mix (10mM) 1#l Sigma, Germany 
DTT mix (10mM) 2#l Invitrogen, Germany 
5X RT 1
st
 Strand Buffer 4#l Invitrogen, Germany 
RT enzyme (200U/ml) 1#l Invitrogen, Germany 
ddH2O up to 20#l Roth, Germany 
 
• Real time RT-PCR mix  
Components Amount Company 
cDNA (200ng/#l) 3#l  
SYBR Green Master Mix (2x) 1#l Applied Biosystems 
Primer mix (10pmol/#l) 1#l  
ddH2O 10.5#l Roth, Germany 
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• Cell lines  
Name Common name Source 
ES-C57BL/6-ATCC BL6 ATCC, Germany 
ES-129-MPI MPI MPI Göttingen 
293FT 293FT Invitrogen, Germany 
BV2 BV2  
 
2.1.2 Cell culture media and reagents 
• Embryonic stem cell (ES) medium  
Components Concentration Company 
DMEM, high glucose  Gibco, Germany 
Fetal bovine serum 15% Gibco, Germany 
Na-pyruvate 0.1mM Gibco, Germany 
L-glutamine 4mM Gibco, Germany 
Non-essential amino acids 0.1mM Gibco, Germany 
L-alanin-L-glutamine 2mM Gibco, Germany 
!-mercaptoethanol 0.1mM Millipore, Germany 
Leukemia inhibitory factor  1000U/ml Millipore, Germany 
 
• Differentiation medium  
Components Concentration Company 
DMEM, high glucose  Gibco, Germany 
Fetal bovine serum 15% Gibco, Germany 
Na-pyruvate 0.1mM Gibco, Germany 
L-glutamine 4mM Gibco, Germany 
Non-essential amino acids 0.1mM Gibco, Germany 
L-alanin-L-glutamine 2mM Gibco, Germany 
!-mercaptoethanol 0.1mM Millipore, Germany 
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• ITSFn medium  
Components Concentration Company 
DMEM/F12 (1:1)  Gibco, Germany 
Insulin 5 #g/ml Sigma, Germany 
Na-selenit 30nM Sigma, Germany 
Transferrin 50#g/ml Millipore, Germany 
Penicillin/Streptomycin (100X) 1% Gibco, Germany 
Fibronectin 5#g/ml Sigma, Germany 
 
• N2 medium  
Components Concentration Company 
DMEM/F12 (1:1)  Gibco, Germany 
L-glutamine 0.048mM Sigma, Germany 
D-glucose (45%) 15.3#g/ml Sigma, Germany 
Penicillin/Streptomycin (100X) 1% Gibco, Germany 
Laminin 1#g/ml Sigma, Germany 
bFGF 5ng/ml R&D Systems, Germany 
 
• Basal medium  
Components Concentration Company 
BME  Gibco, Germany 
Fetal bovine serum 10% Gibco, Germany 
L-glutamine 1% Sigma, Germany 
D-glucose (45%) 1% Sigma, Germany 
Penicillin/Streptomycin (100X) 1% Gibco, Germany 
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• 293FT medium  
Components Concentration Company 
DMEM, low glucose  Gibco, Germany 
Fetal bovine serum 10% Gibco, Germany 
L-glutamine 1% Sigma, Germany 
D-glucose (45%) 1% Sigma, Germany 
Penicillin/Streptomycin (100X) 1% Gibco, Germany 
 
• Other cell culture reagents  
Opti-MEM Gibco, Germany 
Trypsin-EDTA (0.05%) Gibco, Germany 
Gelantine (0.1%) Sigma, Germany 
Poly-L-lysine Sigma, Germany 
PBS (1X) Gibco, Germany 
Tryptan blue Gibco, Germany 
Human beta amyloid 1-42 biotinylated Bachem, Germany 
Normal goat serum Sigma, Germany 
LPS Sigma, Germany 
Recombinant mouse Interferon # HyCult Biotechnology, 
Germany  Fluoresbrite Polychromatic Red Microspheres Polysciences, Germany 
CX3CL1 (Fractalkine) R&D Systems, Germany 
G418 (neomycin) Sigma, Germany 
 
2.1.3 Antibodies 
• Primary antibodies for flow cytometry 
Antibody Host Conjugation Company 
CD16/CD32 (FC-Block) rat    - BD Biosciences, Germany 
CD45 rat biotin BD Biosciences, Germany 
CD11b rat biotin BD Biosciences, Germany 
CD34 
rat 
biotin 
Serotec Laboratories, 
Germany 
CD86 (B7.2) rat biotin BD Biosciences, Germany 
cKit rat biotin BD Biosciences, Germany 
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I-A/I-E (MHC&&) rat biotin BD Biosciences, Germany 
F4/80 
rat 
biotin 
Serotec Laboratories, 
Germany 
CD49d ($4 integrin) rat biotin Abcam, Germany 
CD29 (!1 integrin) hamster biotin Abcam, Germany 
CX3CR1 rabbit    - ProSCI, USA 
IgG2A isotype rat biotin BD Biosciences, Germany 
IgG2B isotype rat biotin BD Biosciences, Germany 
Ig isotype hamster biotin Abcam, Germany 
Whole rabbit serum   Dianova, Germany 
 
• Secondary antibodies for flow cytometry 
Antibody Reactivity Host Conjugation Company 
PE biotin       -  streptavidin Dianova, Germany 
Alexa 488  rabbit goat          - Invitrogen, Germany 
 
• Primary antibodies for immunostaining 
Antibody Reactivity Host Company 
IBa1 mouse rabbit Wako, Germany 
GFP      - rabbit Abcam, Germany 
4G8 (! amyloid) human mouse Signet, Germany 
Nestin mouse mouse Millipore, Germany 
!&&& tubulin mouse mouse Sigma, Germany 
GFAP mouse rabbit Dako Cytomation, Germany 
 
• Secondary antibodies for immunostaining 
Antibody Reactivity Host Conjugation Company 
Cy3 mouse goat           - Dianova, Germany 
Cy3 rabbit goat           - Dianova, Germany 
Alexa 488  rabbit goat           - Invitrogen, Germany 
Alexa 488  mouse goat           - Invitrogen, Germany 
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• Other staining reagents 
 DAPI  Sigma, Germany 
Propidium iodide  Sigma, Germany 
CFSE  Sigma, Germany 
 
2.1.4 Primer sequences  
(all primers were purchased from MWG, Germany) 
Target  Orientation Sequence 
GAPDH  forward 5’- AACTTTGGCATTGTGGAAGG -3’ 
  reverse 5’- GGATGCAGGGATGATGTTCT -3’  
iNOS  forward 5’- AAGCCCCGCTACTACTCCAT -3’ 
  reverse 5’- GCTTCAGGTTCCTGATCCAA -3’ 
TNF$  forward 5’- TCTTCTCATTCCTGCTTGTGG -3’ 
  reverse 5’- AGGGTCTGGGCCATAGAACT -3’ 
IL1!  forward 5’- CTTCCTTGTGCAAGTGTCTG -3’ 
 
 reverse 5’- CAGGTCATTCTCATCACTGTC -
3’ 
TGF!1  forward 5’- CAATTCCTGGCGTTACCTTG -3’ 
  reverse 5’- GCTGAATCGAAAGCCCTGTA -3’ 
 
2.1.5 Consumables 
6-well culture plates Cellstar, VWR International, Germany 
15ml tubes Cellstar, VWR International, Germany 
50ml tubes Sarstedt, Germany 
5ml, 10ml, 25ml pipets Sarstedt, Germany 
Chamber slides Nunc, Germany 
Cryovials VWR International, Germany 
75cm
2
, 175 cm
2
  culture flasks Sarstedt, Germany 
5ml polystyrene round-bottom tubes BD Falcon, Germany 
3cm, 5cm, 10cm culture dishes Sarstedt, Germany 
500#l, 1000 #l plastic tube Eppendorf, Germany 
PCR tubes Biozym Diagnostics, Germany 
10#l, 100#l, 1000#l tips Eppendorf, Germany 
5ml, 10ml syringes Braun,Germany 
Needles Braun, Germany 
Glass slides for cryosectioning Menzel, Germany 
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Bottle top filters (0.25#m pore) Millipore, Germany 
Filters (0.45#m, 0.2#m pore) Sarstedt, Germany 
Transwell (8#m pore filter) Millipore, Germany 
 
2.1.6 Equipment 
Centrifuges Sorvall Discovery 90SE, Hitachi, Germany   
Megafuge, 1.OR. Heraeus, Germany   
Biofuge Fresco, Heraeus, Germany 
Cryostat Microtom HM560, Microm Int., Germany 
Flow cytometer FACSCalibur, BD Bioscience, Germany 
Electrophoresis gel chambers Blomed Analytik GmbH, Germany 
Power supply Amersham Bioscience, Germany 
Heating block Stuart Scientific, Germany 
Incubators Heracell240, Heraeus, Germany 
Laminar air flow workbench Herasafe, Heraeus, Germany 
Microscopes Axiovert40CFL, Zeiss, Germany    
Axiovert200M, Zeizz, Germnay   
Fluoroview1000 Confocal micr., Olympus, 
Germany 
 Axiovert200M, Zeiss, Germnay 
 Fluoview1000 Confocal Microscope, Olympus, Germany 
pH Meter Hanna Instruments, Germany 
Photometer Eppendorf, Germany 
Real time thermocycler ABI Prism 5700 Seqeunce Detection System, 
Applied Biosystems, UK 
Thermocycler T3, Biometra, Germany 
Vortex 2X
2
, VelpScientifica, Germany  
Transplantationsequipment Fine Science Tools, Germany 
 
2.1.7 Software 
Openlab4.0.1  Improvision, Germany 
CorelDRAW Graphics Suite 11, Germany 
EndNote X1 Thomson ISI ResearchSoft, USA 
Microsoft Office Microsoft USA, USA 
Olympus FluoView1.4 Olympus, Germany 
SDS 2.2.2 Applied Biosystems, USA 
Cellquest Pro BD Biosciences, USA 
FlowJo 6.4.7 Tree Star, USA 
KaleidaGraph 4.0 Synergy, USA 
SPSS 16.0 SPSS, USA 
Axiovision 4.6.3 Carl Zeiss Imaging Solutions, Germany 
ImageJ 1.39u NIH, USA 
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2.1.8 Kits and additional reagents 
• RNA and DNA isolation kit 
RNeasy Mini Qiagen, Germany 
RNAse free DNAse Kit Qiagen, Germany 
Endofree Plasmid Maxiprep Qiagen, Germany 
 
• Additional reagents 
Lipofectamine2000 reagent Invitrogen, Germany 
Ampicilin Sigma, Germany 
LB agar and LB media Fluke Biochemika 
DMSO Sigma, Germany 
Glycerol Sigma, Germany 
Tissue tek O.C.T. compound Sciences Services, Germany 
Ethanol Sigma, Germany 
Vectashield Vector Laboratories, USA 
Bovine serum albumin Sigma, Germany 
Hexamer random primers  Roche, Germany 
Ploybrene Sigma, Germany 
 
2.1.9 Anesthethics 
Before transplantation, animals were anesthetized with Ketamin/Xylazin intraperitoneal 
(i.p.) (Ketamin 100 mg per kg body weight and Xylazine 5 mg per kg body weight).   
 
2.2 Mice 
Normal C57/BL6 mice were obtained from Charles River (Sulzfeld, Germany) and bred 
under pathogen free conditions in the animal house. For transplantation experiments 
either neonatal mice C57/BL6 mice or APP23 mice (Novartis, Basel, Switzerland) were 
used. APP23 transgenice mice express human APP751 in the brain. Mutations in the 
APP gene of humans cause early-onset familial AD by affecting the formation of the 
A! peptide, the major constituent of AD plaques. These transgenic mice carried the 
Swedish double mutation at positions 670/671 and developed pathological features 
reminiscent of AD (Sturchler-Pierrat et al., 1997).  
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2.3 Generation of ES cell derived microglial precursors (ESdM) 
The murine ES cell lines ES-C57BL/6-ATCC (BL6) and ES-129-MPI  (MPI) were used 
for the differentiation into microglial precursors. In vitro differentiation was carried out 
using a modified five-step method originally designed to obtain neurons (Lee et al., 
2000). Undifferentiated ES cells (stage 1) were trypsinized and cultured for 2 days on 
gelantine-coated tissue culture plates in the presence of LIF containing ES medium. To 
induce EB formation (stage 2), the cells were dissociated into a single-cell suspension 
and plated onto non-adherent bacterial culture dishes at a density of 2–2.5 &10
4
cells/cm
2
 
in differentiation medium. After 3-4 days, the resulting EBs were plated onto gelatine-
coated dishes. After 24-48 hours, selection and expansion of nestin-positive cells were 
initiated with ITSFn medium supplemented with 5#g/ml fibronectin (stage 3). After 6 
days of selection, cell expansion was initiated in N2 medium supplemented with 1#g/ml 
laminin and 5ng/ml bFGF (stage 4). After 6 days, differentiation was induced by 
removing bFGF and culturing for 21 days in N2 medium and with laminin (stage 5) 
(Tsuchiya et al., 2005). 
 
2.4 Generation and maintenance of ESdM lines 
Proliferation of ESdM was observed 21 days after removal of growth factors. ESdM 
were mechanically isolated and seeded in N2 medium containing 5% FBS to generate 
individual ESdM lines. For further passaging, cells were detached with a cell scraper or 
with 0.05% Trypsin/EDTA. Cells were splitted twice a week and kept in 5% CO2 at 
37°C. Phenotype of each ESdM line was confirmed by flow cytometry. Repeated 
freezing and thawing of cells did not result in loss of phenotype.  
 
2.5 Primary microglia and BV2 cell cultures 
Primary microglia were prepared from brains of postnatal day 3 or 4 (P3 or P4) of 
C57BL/6 mice. In brief, meninges were removed mechanically, and cells were 
dissociated by trituration and cultured in basal medium for 14 days to form a confluent 
mixed glial monolayer. To collect microglial cells, the cultures were shaken on a rotary 
shaker (350 rpm) for 3 hours. The detached microglial cells were seeded on PLL coated 
culture dishes. Purity of the isolated microglia was determined by flow cytometry 
analysis with antibody directed against CD11b (data not shown). 
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The murine BV2 cell line (kindly provided by Dr. Patrick Wunderlich, University of 
Bonn), which was originally immortalized after infection with a v-raf/v-myc 
recombinant retrovirus (Blasi et al., 1990), was maintained at 37°C at 5% CO2 in basal 
medium. 
 
2.6 Immunocytochemistry of cultured cells 
Cells were fixed in 4% paraformaldehyde (PFA) for 10 min, blocked by 10X bovine 
serum albumin (BSA) and 5% normal goat serum (nGS) for 30 min, and then 
immunostained with a polyclonal rabbit antibody directed against IBa1 (1#g/ml) or 
monoclonal rat-anti-CD45, overnight followed by goat-anti-rabbit-Cy3 antibody 
(3#g/ml) or goat-anti-rat Alexa488 antibody (2.5#g/ml). Double-labelling was 
performed by mouse-anti-!&&&-tubulin (6.8#g/ml), rabbit-anti-GFAP (3#g/ml) or mouse-
anti-nestin (1#g/ml) followed by goat-anti-mouse-FITC antibody (3#g/ml) or goat-anti-
rabbit-Cy3 (3#g/ml). Nuclei of immunostained cells were subsequently labeled with 
DAPI (0.1#g/ml). Images were collected by confocal laser scanning microscopy 
(Fluoview 1000, Olympus) or fluorescence microscopy (Axioskop2, Zeiss). 
 
2.7 Flow cytometry analysis  
Cells were collected from the culture dishes by a cell scraper. Cells were first incubated 
for Fc-receptor blockade with a rat monoclonal antibody directed against CD16/CD32 
(5#g/ml), Fc-block, BD Biosciences) and then stained with either biotin-conjugated 
anti-CD45, anti-CD11b, anti-CD86, anti-cKit, anti-I-A/I-E (all 5#g/ml), anti-CD34, 
anti-F4/80, or anti-CD49d ($4 integrin) and CD29 (!1 integrin) (all 10#g/ml) followed 
by PE-conjugated streptavidin (2.5#g/ml). For staining of CX3CR1, cells were blocked 
with 1X BSA, then stained with rabbit anti-CX3CR1 (10 #g/ml) and followed by Alexa 
488 conjugated goat anti rabbit IgG (2.5#g/ml). Isotype-matched control antibodies or 
whole rabbit serum were used as negative controls in the same concentration as the 
responding primary antibody. Data acquisition was performed with a FACSCalibur 
flow cytometer and analysis was done using FlowJo Software.  
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2.8 Analysis of cytokine gene transcripts by real-time RT-PCR  
RNA was isolated with the RNeasy Mini Kit from 0.5 x 10
5
 ESdM, primary microglia 
and BV2 after stimulation for 24 hours by addition of 500ng/ml LPS or murine IFN# 
(500U/ml). Reverse transcription of RNA was performed with SuperScript III reverse 
transcriptase and hexamer random primers. Quantitative RT-PCR with specific 
oligonucleotides was performed with SYBR Green PCR Master Mix using the ABI 
5700 Sequence Detection System and amplification protocol for the ABI 5700 
Sequence Detection System. Amplification specificity was confirmed by the analysis of 
the melting curves. Results were analyzed with the ABI 5700 Sequence Detection 
System v.1.3 after establishing the reaction efficiency for each primer pair. 
Quantification using the delta-CT method was carried out. 
 
2.9 A!  phagocytosis assay 
For in vitro A! phagocytosis, cells were labelled with carboxyfluorescein diacetate 
succinimidyl ester (CFSE). Briefly, for CFSE labeling, cells were washed once in PBS 
and incubated for 5 min at 37°C in 5#M CFSE in 250#l PBS. Then, 5ml PBS was 
added, and cells were further incubated for 5 minutes at 37°C before being washed in 
PBS. Primary microglia, ESdM and BV2 were seeded into PLL coated 4 well chamber 
culture dishes at a density of 2 x 10
4
 cells per well. 24h later, cells were treated with 
biotinylated A!42 peptide (10 #g/ml) for additional 24h. To analyze the phagocytosis 
capacity, cells were fixed in 4% PFA and then permeabilized with 0.1% Triton X-100. 
Fixed cells were stained with Cy3-conjugated streptavidin. Analysis was made using 
fluorescence microscopy. 5 photographs were taken of each well and cells emitting a 
yellow signal were classified as phagocytosing and counted accordingly. 
 
2.10 Chemotaxis assay  
Before seeding, primary microglia, ESdM and BV2 were labeled with CFSE. For CFSE 
labeling, cells were washed once in PBS and incubated for 5 minutes at 37°C in 5#M 
CFSE in 250 #l PBS followed by washing in PBS. Then, 1 x 10
5
 cells were transferred 
into the upper chamber of a transwell system containing 600#l medium with different 
concentrations of CX3CL1 in the lower chamber. After 3 hours incubation period, the 
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number of microglia that had migrated to the lower chamber and on the backside of the 
membrane was counted in three independent areas by fluorescence microscopy. 
 
2.11  Lentiviral transduction of ESdM 
Lentiviral vectors of the third generation, PLL3.7 (provided by L. van Parijs, MIT, 
Cambridge, MA) were used for the transduction of ESdM. The GFP (green fluorescence 
protein) gene was cloned under the pgk-promoter in the PLL3.7 backbone. To allow 
selection of transduced cells the neomycin resistance gene was additionally cloned in 
this vector under the pgk-promoter. For lentiviral particle production the PLL3.7 
plasmid containing the gene of interest was co-transfected together with packaging 
vectors into 293FT cells. Supernatant was collected after 48-72h, and viral particles in 
the supernatant were concentrated by ultracentrifugation for 90 min at 25,000 rpm and 
recovered by suspension in PBS. For ESdM transduction, cells were seeded at 0.5 x 10
6
 
cells/ml into 6-well plates. 50#l of lentiviral particles and 10#g/ml polybrene were 
added to the culture and incubated overnight at 37°C. Medium was changed the next 
day after infection and replaced with normal culture medium. 4 days after transduction 
cells were selected with 250 #g/ml G418.  
 
2.12  Transplantation of ESdM into neonatal brain  
In total, 4 x 10
6
 GFP
+
 ESdM were transplanted into the two hemispheres of the 
midbrain of 2 days old C57BL/6 mice. Mice were sacrified for analysis 28 days after 
transplantation. Animals were perfused transcardially with PBS followed by 4% PFA. 
After post-fixation in fresh fixative, tissue was cryoprotected at 4°C in 30% Sucrose in 
PBS. Tissue was embedded in TissueTek and stored at -80°C before cryosectioning on a 
Micron HM560 cryostat at -20°C.  
For GFP and IBa1 staining, sections were treated for 20 min in 90°C citrate buffer 
followed by blocking with 10X BSA and 5% nGS and 0.1% TritonX for 3 hours. 
Afterwards sections were immunostained overnight with polyclonal rabbit-anti-mouse 
IBa1 (1#g/ml) and Alexa 488-conjugated anti-mouse GFP (4#g/ml). For visualization, 
sections were incubated for 3 hours with secondary fluorescence Cy3-conjugated 
antibody directed against rabbit IgG (3#g/ml). Images were collected by fluorescence 
microscopy (Axioskop2, Zeiss). 
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2.13  Transplantation of ESdM in APP23 mice 
Before transplantation, 24 months old APP23 mice were anesthetized with 
Ketamin/Xylazin (see 3.1.9). Under narcosis, animals were fixed in the stereotactic 
frame, sculls were shaved and a borehole was prepared at 0.52mm to the front and 
2.1mm to the right side. In total, 2 x 10
5
 GFP
+
 ESdM were transplanted into the right 
cortex (1mm deep). Cell suspension was applied over 2 min. Afterwards the borehole 
was fixed with bone wax and was washed with antiseptic solution. Finally, the wound 
was closed with the help of a stapler. To reduce posttraumatic pain, animals received 
Rimadyl (5 mg per kg body weight). After 14 days animals were perfused transcardially 
with PBS followed by 4% PFA. After post-fixation in fresh fixative, tissue was 
cryoprotected at 4°C in 30% Sucrose in PBS. Tissue was embedded in TissueTek and 
stored at -80°C before cryosectioning on a Micron HM560 cryostat at -20°C.  
For detection of aggregated A!, sections were treated for 20 min in 90°C citrate buffer 
followed by blocking with 10X BSA and 0.1% TritonX for 3 hours. Afterwards sections 
were immunostained overnight with monoclonal mouse anti human ! amyloid 
(0.5#g/ml). ). For visualization, sections were incubated for 3 hours with secondary-
fluorescence Cy3-conjugated antibody directed against mouse IgG (3#g/ml). Images 
were collected by fluorescence microscopy (Axioskop2, Zeiss) and analyzed with 
ImageJ. 
 
2.14  Analysis of amyloid !  plaque load 
The amyloid ! plaque burden was analyzed with Image J Software. Two representative 
sections of the transplanted as well as of the contralateral site of each mouse brain were 
imaged under constant light and filter settings. Color pictures were converted to 
grayscale to obtain the best contrast between positive immunoreactivity and 
background. A constant threshold was chosen for all images to detect immunoreactive 
staining. The total number and size of plaques was related to the total area analyzed.   
 
2.15 Statistical analysis 
Data are presented as mean +/- SEM of at least 3 independent experiments. Data were 
analyzed by ANOVA using SPSS computer software. 
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3 Results 
3.1 Microglial precursors are efficiently derived from mES cells 
under standard conditions  
Here we aim to obtain microglial precursors from mES cells according to a modified 
standard protocol (Tsuchiya et al., 2005). mES cells (BL6 and MPI) were cultured in 
LIF containing medium. ES cells formed typical cellular colonies on a layer of 
irradiated MEFs (Fig. 3-1A). EBs were induced from the ES cells after dissociation and 
withdrawal of LIF. EBs were kept in suspension culture for 3-4 days (Fig. 3-1B). Next, 
cells that grow out of EBs were expanded in ITSFn containing culture medium. Under 
this adherent culture condition cells proliferated and resulted in a mixed cell population, 
containing a high number of cells immunostained with specific antibodies directed 
against the intermediate filament protein nestin (Fig. 3-1C). In the next stage, nestin 
positive cells were expanded in the presence of bFGF and laminin. After 7 days, bFGF 
was withdrawn and nestin positive cells differentiated into neuronal precursor cells 
having processes that formed a neuronal network. After 21 days, most of the neuronal 
precursors were immunolabelled with specific antibodies directed against !-III-tubulin 
(Fig. 3-1D). Within these !-III-tubulin positive cells, approximately 25% ± 10% cells 
were detected, which had a microglial-like morphology and were immunostained with 
antibodies directed against the microglial protein IBa1 (Fig. 3-1D). Typically, these 
IBa1 positive cells were forming small cellular colonies, indicating proliferative growth 
of the microglial-like precursor cells (Fig. 3-1D). A subpopulation of cells 
immunolabelled with antibodies directed against GFAP were also detected in these 
cultures. The GFAP+ cells showed typical morphology of astrocytes and lacked co-
immunostaining with specific antibodies directed against CD45 (Fig. 3-1E,F,G; 3-
1H,I,J).  
Results 
 
46 
 
Figure 3-1. Differentiation of mES cells into microglial precursors. A. Phase 
contrast image of cultured ES cell (ES-C57BL/6) clusters on a layer of irradiated MEFs. 
B. Phase contrast image of EBs derived from ES cells (ES-C57BL/6). C. Neural 
precursor cells after 6 days of selection in ITSFn containing medium. Cells were 
immunostained with antibodies directed against nestin (green) and nuclei were counter-
labelled with DAPI (blue). D. Microglial-like cells within a mixed neuronal culture. 
Microglial precursors were immunostained with antibodies directed against IBa1 (red), 
whereas neurons were positive for !-III-tubulin (green). Clusters of microglial cells 
were growing within the neuronal network. E-G. After 21 days of culture in the final 
step of the protocol high numbers of CD45 positive cells were observed. Co-
immunostaining with an antibody specific for astrocytes (GFAP, red) showed no 
colocalization with CD45 (green) positive microglial precursors. H-J. Higher 
magnification of co-immunostaining of astrocytes (red) and microglial precursors 
(green). Scale bar: 100 #m. 
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3.2 Establishment of independent ESdM lines   
The first microglial-like cells appeared approximately 3 weeks after growth factor 
withdrawal (Fig. 3-2A) and started to proliferate forming small cellular colonies 
between neural cells (Fig.3-2B). The cellular colonies were mechanically collected and 
seeded in culture dishes containing culture medium supplemented with 5% FCS. Cells 
grew adherent on the culture dishes and expanded under these culture conditions (Fig. 
3-2C,D). The expanded ESdM lines homogenously showed immunolabelling by 
antibodies directed against Iba1 (Fig. 3-2E,F). Several independent ESdM lines were 
generated from the murine ES cell lines ES-C57BL/6-ATCC and ES-129-MPI (Table 3-
1). The genetic background of the ES cell lines did not interfere with the efficiency to 
generate stably proliferating ESdM lines.  
 
Figure 3-2. Establishment of ESdM lines. A. Phase contrast image of a few bright 
microglia-like cells next to dark neural precursor cells. Magnification: 10X. B. Phase 
contrast image of a bright shining microglial precursor colony within a dense layer of 
neural precursor cells. Magnification: 10X. C. Culture of mechanically isolated 
microglial precursors in culture medium containing FCS. Cells showed constant 
proliferation. Magnification: 10X. D. Higher magnification (20X) of insert in C. E-F. 
Phase contrast image of ESdM and immunostaining with antibodies directed against 
IBa1 (red). All cells of ESdM lines expressed IBa1. Nuclei were counterstained with 
DAPI. Scale bar 30#m.  
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Table 3-1. Summary and origin of established ESdM lines. 
Label of the cell line established Origin of the cell line 
ESDM-1 ES-C57BL/6-ATCC 
ESDM-3 ES-C57BL/6-ATCC 
ESDM-4 ES-C57BL/6-ATCC 
ESDM-5 ES-C57BL/6-ATCC 
ESDM-6 ES-C57BL/6-ATCC 
ESDM-7 ES-C57BL/6-ATCC 
ESDM-8 ES-C57BL/6-ATCC 
ESDM-9 ES-C57BL/6-ATCC 
ESDM-10 ES-C57BL/6-ATCC 
ESDM-11 ES-129-MPI 
ESDM-12 ES-129-MPI 
 
 
 
 
 
3.3 ESdM lines show exponential growth rate behavior 
To determine the growth rate and proliferation ability of ESdM lines, a fixed number of 
cells were seeded and counted 24h, 48h, 72h and 96h later. Experiments were 
performed for three individual ESdM lines and summarized in table 3-2. Taken 
together, ESdM follow an exponential growth rate behavior (Fig. 3-3). 
 
 
Table 3-2. Growth rate of three individual ESdM lines. 
 Number of cells after 
Name 24h 48h 72h 96h 
ESdM-4 P9 1.6 x10
5
 3.5 x10
5
 7.65 x10
5
 3.4 x10
6
 
ESdM-5 P19 3.2 x10
5
 6.75 x10
5
 2.4 x10
6
 6.4 x10
6
 
ESdM-9 P17 4 x10
5
 9.8 x10
5
 2.3 x10
6
 6.2 x10
6
 
Mean  2.9 x10
5
 6.7 x10
5
 1.8 x10
6
 5.3 x10
6
 
SEM 0.6 x10
5
 1.5 x10
5
 4.3 x10
5
 7.9 x10
5
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Figure 3-3. Exponential growth rate behavior of three independent ESdM lines 
and their mean. 
 
 
3.4 ESdM lines have an immunological surface marker profile similar 
to primary microglia  
Flow cytometry analysis was performed from seven individual ESdM lines to assess the 
surface marker profile and to confirm microglial identity. Cell surface molecule 
expression was compared to primary microglial cells as well as to the oncogenically 
transformed microglial cell line BV2. Figure 3-4 shows examples representing the 
surface marker profile of ESdM, BV2 and primary microglia. Each isolated ESdM line 
was marked for nine different epitopes. Detailed expression profile of each line is 
summarized in table 3-3A+B. 
Similar to primary microglia, all ESdM lines showed high expression levels of CD11b 
and CD45. The cell line BV2 showed similar expression of CD11b and CD45 in respect 
to ESdM and primary microglia. F4/80 is an antigen that is exclusively expressed on 
microglia/macrophages. ESdM and the BV2 cell line showed high expression of F4/80, 
whereas primary microglia had lower, but still clear positive, expression of F4/80. In 
contrast to the typical microglial marker proteins none of the three tested cell 
populations were positive for cKit or CD34. Both surface markers are expressed on 
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certain stem cell populations, indicating that ESdM mainly consisted of differentiated 
cells, but not of stem cells. Primary microglia displayed little or very low constitutive 
major histocompatibility complex II (MHC class II) expression. However, expression of 
MHC class II was detected on 4 out of 7 ESdM lines at very low levels (Table 3-3A+B), 
which was comparable to MHC class II levels on BV2. As the principal immune 
effector cells resident within the CNS, microglia form adhesive interactions with other 
cell types and CNS substrates via members of the integrin superfamily. These 
molecules are expressed in the cell surface as heterodimers. As examples of the integrin 
superfamily, expression of two subunits ($4 integrin and !1 integrin) forming a 
heterodimer were analyzed. ESdM, BV2 as well as primary microglia showed high 
levels of $4 integrin and !1 integrin. Interactions between the growing family of B7 co-
stimulatory ligands and their receptors are increasingly recognized as important 
pathways for co-stimulation and/or inhibition of immune responses. ESdM showed in 6 
out of 7 lines high expression of B7.2 in line with BV2, whereas primary microglia 
showed a moderate expression of B7.2 compared to ESdM. 
In summary, expression profile of cell surface receptors detected by flow cytometry on 
ESdM was very similar to primary microglia. ESdM showed undetectable levels of 
stem cell markers, but showed expression of markers identifying a population belonging 
to the myeloid lineage.  
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Table 3-3A. Surface marker expression profile of seven individual ESdM lines. 
ESdM lines were labeled for nine epitopes and the corresponding isotype controls. 
Values are expressed as mean fluorescent intensity (MFI) of each marker. Bold typed 
values indicate that the expression of the marker was regarded as positive (MFI ' 15). 
Line  
Passage # 
ESDM-1 
P11 
ESDM-
3 P2 
ESDM-
4 P2 
ESDM-
5 P2 
ESDM-
6 P2 
ESDM-
8 P2 
ESDM-
9 P2 
rat IgG2b  7.5 6.2 4.7 6.0 8.1 7.6 5.0 
rat IgG2A  13 8.1 6.7 7.2 8.5 7.0 6.3 
hamster IgG  7.2 6.7 5.3 6.3 10.1 6.4 4.9 
cKit 12.5 8.5 7.0 13 10.5 7.9 7.2 
CD11b 176 226 153 109 211 130 222 
CD45 750 184 249 40.7 709 99.5 210 
F4/80 70.2 47.4 235 281 48.3 25.3 42.3 
CD34 10.9 6.77 9.7 8.3 10.1 6.2 4.9 
B7.2 88.9 57.7 106 15.7 60.7 62.3 66.6 
$4 integrin 103 176 261 244 40.4 41.5 52.1 
!1 integrin 93.7 103 240 172 237 49 70.6 
MHC class II 22.6 12.5 4.9 15.9 15 12.3 10.9 
 
 
 
 
Table 3-3B. Surface marker expression profile of BV2 and primary microglia. 
Both cell types were labeled for nine epitopes and the corresponding isotype controls. 
Values are expressed as mean fluorescent intensity (MFI) of each marker. Bold typed 
values indicate that the expression of the marker was regarded as positive (MFI ' 15). 
Cell type BV2 
Primary 
microglia 
rat IgG2b  6.9 14.9 
rat IgG2A  8.8 10.2 
hamster IgG  6.4 9.47 
cKit 9.6 14.9 
CD11b 503 532 
CD45 538 238 
F4/80 285 48.8 
CD34 14.4 15.3 
B7.2 430 29.4 
$4 integrin 561 97.8 
!1 integrin 449 89.9 
MHC class II 19.5 12.2 
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Figure 3-4. Representative flow cytometry analysis of ESdM, primary microglia 
and BV2. ESdM, BV2 and primary microglia are similar in the expression pattern of 
cKit, CD11b, CD45, CD34, !1 integrin and MHC class II. Primary microglia show 
decreased levels of F4/80, $4 integrin and B7.2 compared to ESdM and BV2. 
Individual isotype control antibodies are represented as filled grey histogram.  
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3.5 ESdM keep immunological profile of microglia over long-term 
culture 
To prove the stability of microglial markers expressed on ESdM, ESdM were cultured 
over time. Every 5
th
 passage ESdM were analyzed by flow cytometry for some typical 
microglial markers. No relevant change of cell surface molecule expression of CD11b, 
CD45, F4/80, B7.2, $4 integrin, !1 integrin  and MHC class II was observed over 20 
passages (Table 3-4). After 25 passages the analyzed ESdM line showed decreased 
expression of all seven checked markers indicating that ESdM phenotype is not stable 
over long culture time since ESdM are not oncogenically transformed.   
 
 
 
Table 3-4. Microglial surface marker profile of ESdM over 25 passages. ESdM 
were cultured as described. Every 5
th
 passage surface marker profile of ESdM was 
analyzed. Values are expressed as MFI of each marker. 
Line  
Passage # 
ESDM-5 
P10 
ESDM-5 
P15 
ESDM-5 
P20 
ESDM-5 
P25 
rat IgG2b  9.36 4.16 6.3 3.47 
rat IgG2A  7.51 4.97 7.64 3.57 
hamster IgG  8.35 4.33 6.24 3.7 
CD11b 193 145 327 13.3 
CD45 276 274 474 39 
F4/80 230 138 363 20.6 
B7.2 73.8 60.1 83.7 7.14 
$4 integrin 286 127 186 26.4 
!1 integrin 389 208 429 29.3 
MHC class II 16.6 12.3 15.4 3.77 
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3.6 Functional characterization of ESdM in vitro 
3.6.1 Pro-inflammatory stimuli influence the transcription of pro- and anti-
inflammatory mediators in ESdM 
One typical feature of microglia is the inducibility of proinflammatory cytokines and of 
reactive oxygen species gene transcripts after immune stimulation. Therefore, we 
determined the gene transcript levels for TNF-", IL-1!, iNOS and TGF-!1 by real-time 
RT-PCR in ESdM lines after stimulation with IFN-# or LPS, and compared them to 
primary microglia and the cell line BV2.  
LPS stimulation significantly increased mRNA transcripts of iNOS in ESdM (49.6 fold 
+/- 15.9) as well as in primary microglia (55.8 fold +/- 34.5), whereas BV2 showed less 
upregulation of NOS2 gene transcripts (14 fold +/- 1.1)). TNF$ was strongly 
upregulated after LPS stimulation in primary microglia (14.2 fold +/- 2.3), but only 
slightly, but still significantly, in ESdM as well as in BV2 (both 2.1 fold +/- 0.2). LPS 
stimulation had almost no effect on IL1! gene transcripts in BV2 (2.1 fold +/- 0.4), but 
showed clear upregulation of IL1! gene transcripts in ESdM (11.9 fold +/- 2.5) and in 
primary microglia (68 fold +/- 10.1). Downregulation of anti-inflammatory cytokines 
like TGF! was observed after LPS stimulation in primary microglia (0.5 fold +/- 0.1) 
and in ESdM (0.7 fold +/- 0.1), but was absent in BV2 (no significant change to non 
stimulated) (Fig. 3-5A). 
After IFN-# stimulation, ESdM showed significant upregulation of iNOS gene 
transcripts (461.4 fold +/- 97.5), whereas TNF$ was only slightly upregulated (1.5 fold 
+/- 0.2). Primary microglia showed significant upregulation of iNOS transcripts (% 1770 
fold) and upregulation of TNF$ (% 4.3 fold). BV2 showed also upregulation of iNOS (% 
1770 fold) and TNF$ (2.5 fold +/- 0.4) gene transcripts. Downregulation of TGF! was 
observed in all three cell types after IFN# stimulation. IL1! gene transcription was 
almost unchanged in all three cell types after IFN# stimulation (Fig. 3-5B).  
Taken together, ESdM have a similar response in gene transcription to pro-
inflammatory stimuli compared to primary microglia. 
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Figure 3-5. Cytokine gene transcripts analysis of ESdM, BV2 and primary 
microglia after LPS (A) and IFN#  (B) stimulation. A. LPS stimulation upregulated 
significantly iNOS and TNF$ gene transcripts in all three cell types. However, LPS 
stimulation increased IL1! gene transcripts in ESdM and primary microglia and but 
showed almost no effect in BV2. Downregulation of anti-inflammatory cytokines like 
TGF! was observed after LPS stimulation in primary microglia and in ESdM, but was 
absent in BV2 (no significant change to non stimulated). B. After IFN# stimulation all 
three cell types showed dramatic upregulation of iNOS gene transcripts, whereas IL1! 
gene transcription was almost unchanged. TNF$ gene transcripts were only slightly 
upregulated in ESdM, but moderately increased in primary microglia and BV2. 
Downregulation of TGF! was observed in all three cell types after IFN# stimulation. 
Data are represented as means +/- SEM of three individual experiments and were 
analyzed using one-way ANOVA (*p<0.05; n=3). 
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3.6.2 Migratory potential of ESdM towards fractalkine 
The major role of chemokines is to guide the migration of cells. Cells that are attracted 
by chemokines follow a signal of increasing chemokine concentration towards the 
source of the chemokine. The biological effects of all chemokines are mediated by 
specific receptors that belong to the large family of G protein-coupled receptors with 
seven transmembrane regions. In the CNS, fractalkine (CX3CL1) is the most prominent 
chemokine and is constitutively expressed in neurons. It has several singular features 
that make it particularly appealing in the context of neuroinflammation and 
neuroprotection. Its receptor CX3CR1 (fractalkine receptor) is also highly expressed in 
the CNS, primarily by microglia. Thus, we checked the migratory capacity of ESdM 
towards fractalkine and compared it with primary microglia as well as with BV2. 
However, before performing the chemotaxis assay, ESdM were analyzed for the 
presence of the fractalkine receptor. Flow cytometry analysis showed that ESdM were 
clearly positive for CX3CR1 (Fig. 3-6A).  
Next, to determine optimal concentration of fractalkine for in vitro migration, CFSE 
labeled ESdM cells were seeded at a density of 1 x10
5
 cells in the upper chamber of the 
transwell. Increasing concentrations of fractalkine (0-20ng/ml) were added to the lower 
chamber of the transwell system. The cells were kept for 3 hours at 37°C. Migrated 
cells into the medium as well as under the transwell were counted under UV microscope 
and regarded as migrated. As demonstrated in Figure 3-5B, ESdM were attracted to the 
chemokine stimulus in a concentration dependent manner. Optimal concentration for the 
migration of ESdM was assessed at 15ng/ml fractalkine. At higher concentrations 
(20ng/ml), ESdM showed even less migration (Fig. 3-6B).    
To compare the in vitro migration of ESdM with primary microglia and BV2, all three 
cell types were CFSE labeled and assessed to 15ng/ml fractalkine in the transwell 
migration system. Under basal conditions, there was low migration of primary 
microglia (44 counted cells +/- 7.4), however under the CX3CL1 gradient migration 
was increased about 3 fold (137 counted cells +/- 26.3). Migration capacity of ESdM 
was very similar to primary microglia under basal conditions. In line with primary 
microglia ESdM showed about 3 fold increased migration (113.7 counted cells +/- 13.7) 
under the CX3CL1 gradient. In contrast, BV2 already showed high basal migration 
(95.8 counted cells +/- 19.2), and migration under CX3CL1 condition was only 
increased about 1.4 fold (131 counted cells +/- 22.8) (Fig. 3-6C). 
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Figure 3-6. Migratory capacity of ESdM. A. Flow cytometry analysis of ESdM with 
an antibody directed against CX3CR1 (fractalkine receptor). Isotype control antibody is 
represented as filled grey histogram. B. Migration of ESdM towards the ligand 
CX3CL1 (fractalkine) was concentration-dependent. C. Migratory capacity towards 
fractalkine of ESdM was compared to primary microglia or BV2 cell line. ESdM 
showed directed migration comparable to primary microglia, whereas BV2 showed 
almost no specific migration. Data are presented as means +/- SEM of three 
independent experiments and were analyzed using one-way ANOVA (*p<0.05; n=3). 
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3.6.3 A!  uptake of ESdM in vitro 
Aggregation of A! is one of the key pathological hallmarks of AD. In addition, 
phagocytic capacity is an important functional aspect of primary microglia. In vitro, 
microglial cells have been demonstrated to have the ability to clear A! efficiently. 
Therefore we aimed to compare the phagocytic potential of ESdM with primary 
microglia and the microglial cell line BV2. For that, CFSE labeled cells were seeded on 
chamber slides and stimulated for 24h with the pro-inflammatory agent LPS. 
Afterwards, biotinylated human A!1-42 was applied to the cells for 24h. After fixation 
and staining of A!1-42 with Cy3 conjugated streptavidin, cells emitting a yellow signal 
were counted as having phagocytosed (Fig. 3-7A).  
Compared to primary microglia ESdM showed slightly less A! phagocytosis under 
basal conditions. However, after LPS stimulation ESdM increased A! phagocytosis 
from 29% +/- 5.2% to 52.1% +/- 6.3%. Primary microglia showed highest capacity in 
A! phagocytosis after stimulation with 500ng/ml LPS (from 47.6% +/- 5.5% to 83.9% 
+/- 4.3%). The microglial cell line BV2 had compared to the both other cell types the 
lowest A! phagocytosis. Under basal conditions, only 21.9% +/- 6.9% of cell were 
phagocytosing and upon stimulation, BV2 increased phagocytosis to only 43.4 +/- 6.8% 
(Fig. 3-7B). 
Taken together these data show that ESdM efficiently take up aggregated A! in vitro at 
a comparable level to primary microglia, and superior to BV2 cell line. 
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Figure 3-7. A!  phagocytosis of ESdM. A. Representative pictures of CFSE labeled 
ESdM having phagocytosed Cy3 labeled A!1-42. Cells emitting a yellow signal were 
counted as phagocytosing. B. A! phagocytosis of ESdM, BV2 and primary microglia 
under basal conditions and after treatment with LPS for 24h. All three cell types showed 
increased phagocytosis after LPS stimulation. However primary microglia showed 
highest, but not significant, A! phagocytosis under both conditions. Data are presented 
as means +/- SEM of three independent experiments and were analyzed using one-way 
ANOVA (*p<0.05; n=3).  
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3.6.4 ESdM exhibit microglial identity in vivo 
Under non pathological conditions, microglia exhibit a ramified morphology in vivo. 
For in vivo detection, ESdM were genetically modified with lentiviral particles 
produced from a vector overexpressing GFP and the antibiotic selection marker 
neomycin under ubiquitous promoters pgk (phosphoglycerate kinase) (Fig. 3-9A). 
ESdM were lentivirally transduced with particles leading to GFP expression in 8% +/- 
3.2 % of cells at 3 days after transduction. Then an antibiotic selection procedure was 
applied over 7 days. After transduction and selection, ESdM were homogenously 
expressing GFP (Fig. 3-9B). To analyze the engraftment potential of ESdM in vivo, 
GFP
+
 ESdM were transplanted into both hemispheres of postnatal day 2 (P2) mice. In 
total, 2x10
6
 cells were transplanted by injection in each hemisphere. After 28 days 
animals were sacrificed and analyzed by immunohistochemistry. GFP
+
 cells were found 
engrafted within the brain parenchyma having a ramified morphology (Fig. 3-9C). 
Immunofluorescence labeling with specific antibodies directed against IBa1 was 
performed. Many (82.9% +/- 7.3%) of IBa1+ cells showed immunoreactivity for GFP. 
Data indicate that upon transplantation ESdM can integrate into the normal CNS and 
might function there as microglia. 
 
3.7 ESdM as a tool for a cell therapy approach in APP23 mice  
After in vitro characterization, ESdM seem to be a good tool in a cellular therapy 
approach of AD since ESdM have been shown to take up A!. At first, ESdM were 
transduced with lentiviral particles to overexpress GFP followed by antibiotic selection 
to enhance GFP expression (Fig. 3.9A+B).  
Systemic transplantation (into tail vein) of GFP
+
 ESdM was not successful since ESdM 
were not detected in the target region (data not shown). It seemed that ESdM were not 
able to overcome the blood brain barrier to enter the region of interests.  
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Figure 3-9. ESdM exhibit a ramified morphology after transplantation into 
neonatal mice. A. Schematic representation of the lentiviral construct to genetically 
modify ESdM. B. After transduction and selection ESdM express homogenously GFP. 
Scale bar 100#m. C. Lentiviral transduced GFP+ cells were transplanted into P2 mice. 
After 28 days brains were analyzed for the presence of GFP
+
 cells which also co-
immunostained with the microglial marker IBa1. GFP
+
 cell were found in a ramified 
morphology and were also reactive for IBa1. Scale bar 20#m. 
 
To overcome this inhibitory condition, GFP
+
 ESdM were stereotactically injected to the 
region of interest, here the cortex of APP23 mice. In total, 4 APP23 mice were injected 
with 2x10
5
 GFP
+
 ESdM and analyzed for the presence of A! at the transplantation site. 
As control, the exact cortical area found on the contralateral site of each transplanted 
brain was analyzed in the same manner. Upon transplantation, GFP
+
 ESdM were 
detected in close proximity of the transplantation site and stayed there in circle-like area 
(Fig. 3-10A+D). Migration to other areas except the transplantation site was not 
observed. Immunostaining for aggregated A! showed that at the transplantation site 
significant less positive staining was present. Thus, ESdM seemed to efficiently clear 
A! after in vivo transplantation in their close proximity (Fig. 3-10A+B). Some A! 
aggregates were still found in the area of transplantation, and in between these plaques 
co-localization of GFP
+
 ESdM with A! immunostaining was detected indicating that 
ESdM were phagocytosing A! (Fig. 3-10B-F, white arrows). 
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Quantification of the A! plaque burden in the transplanted region and in the 
corresponding contralateral site (Fig. 3-11A) showed that in the transplanted area the 
mean plaque size was significantly decreased to 17,690#m
2
 +/- 112#m
2
 compared to 
65,266#m
2
 +/- 108#m
2
 measured in the contralateral site (Fig. 3-11C). In addition, 
transplantation of ESdM resulted in more but smaller plaques (190 counted plaques 
with a size between 20-400#m
2
) and only 2 counted plaques with a size above 400 #m
2
. 
In contrast, the contralateral site had 79 counted plaques with a size between 20-400#m
2
 
and 28 counted plaques with a size above 400#m
2
 reaching a size up to 6900#m
2
. This 
plaque size distribution indicates that ESdM were able to disrupt A! aggregates (Fig. 3-
11B). Taken together, the results of the cellular therapy approach of ESdM in an animal 
model of Alzheimer’s disease indicate that ESdM are capable to remove plaques after 
stereotactic injection.    
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Figure 3-10. ESdM efficiently remove A! aggregates after stereotactic injection. 
A.+B. At the site of transplantation ESdM removed most of all A! aggregates. C.-F. 
GFP+ ESdM co-localize with A! immunostaining indicating the presence of active 
phagocytosis of A!. Scale bar 50#m, except in F 10#m. 
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Figure 3-11. Quantification of A!  plaque burden after transplantation. A. 
Representative images of the transplanted and the contralateral site used for 
quantification of A! plaque burden. B. In the transplanted area significantly more but 
smaller plaques are detected. In addition, the mean plaque size is smaller in the 
transplanted hemisphere compared to the contralateral site indicating a beneficial effect 
of the cell therapy. C. Looking at the total plaque area, transplanted regions had 
significantly less positive staining for aggregated A! compared to the contralateral site. 
Data are presented as box plot (B) or as means +/- SEM (C) of four individual animals 
and were analyzed using one-way ANOVA (*p<0.05; n=4).    
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4 Discussion 
4.1 ESdM – an alternative to primary microglia?  
Our study was initiated by a pioneering work from Tsuchiya and colleagues, who 
suggested that a small population of microglial-like cells can be found next to neural 
cells which differentiated out of mouse EBs (Tsuchiya et al., 2005). Their 
differentiation protocol was based on a protocol for the generation of dopaminergic 
neurons (Lee et al., 2000). During neuronal differentiation they found a ‘contaminating’ 
population positively stained for IBa1 and CD45, which they isolated out of the mixed 
neuronal culture with a gradient method for further investigations (Tsuchiya et al., 
2005). However, they did not report any generation of stable proliferating microglial 
cell lines and do not provide an extensive characterization of their ES cell derived 
microglial-like cells. In this work a population of microglial precursors was 
differentiated from two different strains of mES cells. According to our modified 
differentiation protocol we were now able to induce microglial precursors from mES 
cells in a consistent and efficient manner. In contrast to the previous report (Tsuchiya et 
al., 2005) our differentiation resulted in a high amount of proliferative microglial 
precursors. Upon mechanical isolation we were even able to keep ESdM lines in culture 
over 25 passages, sufficient to generate high cell amounts for biochemical analysis, cell 
screening assays or experimental cell therapy experiments.  
 
4.1.1 Phenotype of ESdM 
Immunostaining during the differentiation protocol revealed an IBa1
+
 and CD45
+
 cell 
population within a neuronal network of !-III-tubulin+ cells and next to a subpopulation 
of GFAP
+
 cells, a classical marker for astrocytes. Interestingly, after isolation we were 
able to further propagate these IBa1/CD45
+
 cells under defined culture conditions 
leading to a homogenous population of cells comparable in their phenotype to primary 
microglia. Cells did not show any changes in cell surface protein expression after 
freezing and thawing procedure allowing straightforward handling.  
The origin of microglia is still widely discussed. The most widely accepted hypothesis 
is that microglia arise from the mesoderm and colonize the CNS in two waves at early 
embryonic and fetal development, although it is still questioned whether a 
subpopulation is derived from the neuroectoderm lineage (Chan et al., 2007). Findings 
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suggest that there is a developmental window during embryogenesis where microglial 
cells colonize the nervous system. There is evidence that two separate ‘populations’ of 
microglia one originating from an undefined precursor during embryonic development 
the other from fetal myeloid precursors contribute to the colonization of the CNS. 
Indeed it is unclear whether microglia may derive from more than one type of 
progenitor cells during embryonic and fetal development (Chan et al., 2007). In the 
healthy adult brain it is assumed that microglia are replenished intrinsically and do not 
require significant turnover from circulating blood progenitors, whereas it is widely 
believed that under detrimental pathologic conditions and inflammatory brain diseases 
bone marrow derived inflammatory monocytes are recruited from the blood into the 
brain (Simard and Rivest, 2004; Simard et al., 2006). However, recent findings strongly 
suggested that maintenance and local expansion of microglia are solely dependent on 
the self-renewal of CNS resident cells even in denervation or CNS neurodegenerative 
disease (Ajami et al., 2007). Our differentiation procedure to derive microglial 
precursors from ES cells is based on a classical protocol for obtaining neurons via 
neuroectodermal differentiation. Thus, data favor the view that microglia might derive 
from a neuroectodermal progenitor cell. However, we cannot exclude that a few 
mesodermal cells from the stage of EB formation survive in the culture during the 
following steps of neuroectodermal differentiation and give rise to microglia at later 
stages of neuronal differentiation. Clonal analysis of single cells during differentiation 
of ES cells to microglia would bring light to the question of microglia’s origin and 
whether microglia originating from neuroepithelia could provide a source for microglia 
turnover in the brain.  
Since being first described, several markers to define the phenotype of microglia have 
been proposed although there is no single marker to definitely distinguish between 
microglia and tissue macrophages. In literature, ramified microglia are described to 
constitutively express CD11b/CD18 complex, as well as CD45 (Guillemin and Brew, 
2004). CD45 is a membrane tyrosine phosphatase that is used to distinguish cells of the 
hematopoietic lineage from the endothelial lineage. All ESdM lines analyzed in this 
work were highly immunoreactive for CD11b, CD45 and F4/80. F4/80 is exclusively 
expressed on microglia/macrophages (Austyn and Gordon, 1981). Although ESdM 
were generated from mES cells, almost no detectable levels of cKit, a stem cell marker, 
were expressed on all analyzed ESdM lines indicating that all cells committed to 
differentiation. CD34, which is expressed on hematopoetic stem cells, was also absent 
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on all analyzed ESdM lines. Expression and/or induction of immune effector molecules 
is a prerequisite of microglia for antigen presentation, co-stimulation of bystander cells, 
as well as adhesion. Antigen presentation depends on MHC class I and II molecules. 
Although it is reported that microglia can successfully present antigen, it is known that 
under non-activated conditions, microglia do not express high levels of MHC class II 
(Benveniste et al., 2001). This is in harmony with our findings, since ESdM displayed 
only very low amount of MHC class II and primary microglia do not display any MHC 
class II. The co-stimulatory molecule B7.2 as well as two members of the integrin 
family were found to be expressed on ESdM indicating that they can exhibit 
immunoregulatory functions. Taken together the analyzed surface antigen expression of 
all ESdM lines was almost indistinguishable to primary microglia.  
Long-term propagation up to passage number 25 did not result in any change of the 
surface marker profile. Nevertheless there was a reduction of fluorescence intensity of 
several cell surface protein in the flow cytometry analysis after passage 25. Changes in 
cell surface proteins after 25 passages could be explained by a physiological limit of 
doublings of differentiated cells since ESdM lines were not manipulated with oncogenic 
genes.  
To analyze the engraftment potential of ESdM in vivo, ESdM were lentivirally 
transduced with GFP and transplanted into both hemispheres of P2 mice. The GFP
+
 
cells were found engrafted within the brain parenchyma and had a ramified 
morphology. Microglial identity was confirmed by colocalization with the microglial 
marker IBa1. Thus, from our observation we can conclude that upon transplantation 
ESdM can integrate into the normal CNS and might function there as microglia.  
 
4.1.2 Functionality of ESdM 
The inducibility of proinflammatory cytokines and reactive oxygen species after pro-
inflammatory triggers is a typical feature of microglia (Hanisch, 2002). In our 
experimental paradigm we used two different inflammatory triggers (LPS and IFN#) to 
study cytokine gene transcription by real-time PCR. In general, ESdM always showed a 
similar response in gene transcription compared to primary microglia, but real-time 
PCR analysis also manifested slight differences between primary microglia, ESdM and 
BV2. In detail, ESdM upregulated IL1! gene transcription about 12 fold, whereas 
primary microglia showed 68 fold increase after LPS stimulation. Interestingly, BV2 
was not able to upregulate IL1! gene transcription at all, which might be a consequence 
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of oncogenic transformation. One should keep in mind that ESdM are generated 
completely in vitro meaning that any microglia coming out of this differentiation 
procedure never received any stimulus from the CNS environment. This lack of intrinsic 
and/or extrinsic factors might be the reason for the slightly different behavior of ESdM 
after inflammatory stimulus. Taking this into consideration it is reasonable to define the 
isolated population rather as microglial precursors than microglia.  
Fractalkine is constitutively expressed in neurons, as soluble and a membrane-bound 
form, both promoting chemotaxis (Re and Przedborski, 2006). A transgenic mice 
having a reporter gene encoding GFP under the CX3CR1 locus clearly demonstrated 
that microglia are the only cell type expressing receptors for fractalkine in the CNS 
(Jung et al., 2000). Accordingly, ESdM expressed the fractalkine receptor and displayed 
migration towards fractalkine very similar to primary microglia in an in vitro transwell 
migration system. Interestingly, BV2 lacked chemokine-directed migration towards 
fractalkine, although they displayed undirected constitutive high migratory activity. 
Taking these observations together it seems that ESdM had the same strength in 
responding to fractalkine compared to primary microglia, whereas BV2 showed already 
a high undirected migratory activity under basal conditions. The answer if oncogenic 
transformation brings the cell to a pre-activated status and so leading to non-specific 
migration of these cells remains open.   
Many cells of the immune system are able to phagocytose particles via a set of 
phagocytic receptors and digest the taken-up material by a professional lysosomal 
machinery. Microglial phagocytosis is a highly coordinated process, which is mainly 
regulated by signals that microglia receive from their environment (Napoli and 
Neumann, 2008). Standard in vitro assays to determine the phagocytic capacity of cells 
include the phagocytosis of microsphere beads, apoptotic neurons and/or aggregated 
A!. Because of the functional relevance in an animal model of AD, we focused here on 
the phagocytosis of aggregated A! to demonstrate a functional phagocytic capacity of 
ESdM in vitro (Bard et al., 2000). We showed that ESdM are able to phagocytose A! 
peptides and that this effect is significantly increased after LPS stimulation. Levels of 
A! uptake of ESdM under LPS stimulated were comparable to primary microglia and 
superior to BV2. The capability of ESdM to take A! aggregates up makes them an 
interesting tool to use them in a cell therapy approach of an animal model of AD 
(discussed in detail later).   
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Microglia differentiated from ES cells might be a future tool to have sufficient amounts 
of cells for further investigations. Our results show that ES cells can differentiate into 
functional microglial precursors. In minor points ESdM looked less mature compared to 
primary microglia, but it has to be proven if any treatment, i.e. long-term application of 
GMCSF, would improve ESdM maturity. In summary, we were able to prove that the 
phenotype and the functionality of ESdM lines were very similar to primary microglia 
and in several aspects clearly superior to the oncogenic transformed microglial cell line 
BV2. Therefore, ESdM are a novel optimized tool to study microglial function in vitro 
and to apply them for cell therapy approaches. 
Except from biopsied or post-mortem tissue, the derivation of functional microglial 
cells from the human’s brain is almost impossible. The analysis of mouse ESdM 
showed in a convincing manner that cells derived from ES cells are able to substitute to 
a certain degree primary cells. Therefore, the differentiation of microglial precursors 
from human ES cells would overcome the obstacle always coming along with human 
tissue. Human ESdM would give the advantage to study microglial functions in the 
human brain. Our future aim will be to adapt the protocol for the differentiation of 
human ES cells to microglial precursors.  
 
4.2 ESdM – a tool in a therapeutic approach of an animal model of 
Alzheimer’s disease 
After the detailed characterization of ESdM, it becomes striking to analyze their 
potential in a mouse model of AD. Until now there is low experimental evidence 
whether the phagocytic function of exogenously applied microglia effectively 
contributes to A! clearance in the CNS. Indeed, there is only one group that reported 
the administration of exogenously applied microglia for a cell therapeutic approach in a 
rat animal model of AD. In 2007, Takata and coworkers showed that microglial 
transplantation increased A! clearance (Takata et al., 2007). However, the rat model of 
AD was not reflecting the situation of AD as good as common mouse models. In this 
animal model plaques are not formed due to genetic mutations, but due to exogenously 
applied A!42 aggregates. Thus the rat AD model cannot really reflect the 
pathoimmunological aspects of AD and accordingly findings have to be critically 
evaluated.  
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The route of injection for cell application in CNS therapy needs to be accurately chosen. 
The less invading cell application is the intravenous (i.v.) injection into the tail vein of 
the host. After entering the circulation homing of cells to the target tissue can be 
achieved. In CNS cell therapy approach, one prerequisite is that cells have the ability to 
overcome the blood brain barrier. In our experimental paradigm, we were not able to 
detect GFP
+
 cells in the brain parenchyma after i.v. injection into the tail vein of APP23 
mice. It cannot be excluded that ESdM were not able to overcome the blood brain 
barrier and therefore were homed to other tissues like spleen or liver. Since we did not 
achieve to target cells to the CNS, we did not follow up any further investigations about 
the destination of ESdM after i.v. injection.   
Several groups have demonstrated that bone marrow-derived cells are able to become 
brain macrophages, and a major role of bone marrow-derived brain macrophages in A! 
clearance is also suggested (Simard and Rivest, 2004; Malm et al., 2005; Simard et al., 
2006). Thus, bone marrow cells may be a suitable source of microglial-like progenitors 
in clinical application. However, recent reports provided the evidence that irradiation, 
which is used to create bone-marrow chimerism, had influence on the permeability of 
the blood brain barrier leading to migration of bone marrow derived cells to the CNS, 
which is normally not achieved under physiologic conditions (Ajami et al., 2007; 
Mildner et al., 2007). According to this premise and in regard with our difficulties to 
overcome the blood brain barrier we challenged our APP transgenic mice by irradiation 
before we applied i.v. GFP
+
 ESdM. However, we were again not able to detect GFP
+
 
cells in the CNS after i.v. injection of ESdM in irradiated APP transgenic mice.  
Alternatively, there are studies describing the migration of exogenously applied 
microglia into the brain of gerbils after intra-arterial injection (Imai et al., 1997; Suzuki 
et al., 2001). Intra-arterial application into the subclavian artery avoids the circulation of 
cells through the body and facilitates the direct entry of cells into the brain. This 
application route may be a promising alternative, however practical realization is very 
difficult in mice.   
To overcome the limitation of the blood brain barrier and to introduce our cells next to 
A! plaques, we switched our experimental setup to stereotactic local injection of cells. 
GFP
+
 ESdM were locally injected to the cortex of APP23 mice. Careful analysis 
revealed that ESdM showed limited migration towards surrounding plaques after 
transplantion. Interestingly the area that was covered by ESdM after local injection 
showed a significantly decreased total plaque area as well as smaller plaques. The 
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observations suggest that ESdM were restricted in their migration behavior after local 
injection, however their capacity to phagocytose A! contributed to beneficial clearance 
of their microenvironment. The question whether ESdM transplantation might influence 
residential cells around the A! deposits, such as neurons, astrocytes, and endogenous 
microglia, is still outstanding. Careful morphological analysis of the surrounding tissue 
is in progress.  
The lack of migration of ESdM after transplantation is in contrast to our results we 
obtained in the in vitro migration assay, where ESdM follow a precise gradient of 
fractalkine. One could speculate that after cell transplantation into brains of animals 
with progressed pathology, cells are overwhelmed by signals from the environment 
leading to a desensitization of migration, which renders them non-responsive to their 
environment and holds them at their transplantation origin.  
The protective function of microglia in A! clearance is not negligible, but careful 
interpretation of literature raises important questions. Why does A! continue to 
accumulate, and why does AD pathology progress despite continued microglial 
recruitment? There are two main theories, which could explain the failure of microglia 
to hinder AD progression, (1) microglial cells become overwhelmed by the excess 
amount of A! produced and cannot keep up with the pace of A! accumulation, (2) the 
phenotype of accumulating microglia changes and these cells become more pro-
inflammatory and lose their ability to clear A!, resulting in reduced A! phagocytosis 
and degradation, and increased A! generation/accumulation. Recently, Hickman and 
coworkers provided evidence that the inflammatory response in AD is a ‘double-edged 
sword’. Early recruitment of microglia to the sites of A! accumulation as part of the 
attempt to clear these neurotoxic aggregates delays AD progression. However, with 
increasing age, recruited microglia become dysfunctional and show reduced ability to 
clear A!, but maintain their ability to produce pro-inflammatory cytokines leading to 
disease progression (Hickman et al., 2008).  
In summary, we demonstrated the possible usefulness of exogenously transplanted 
ESdM for the clearance of A! in the brain of APP23 mice. Our data confirm that 
microglia, which were not influenced in their clearance capacity due to ongoing 
inflammatory disease progression, retain their ability to efficiently phagocytose 
aggregated A!. Limiting factors in our model were the lack of migration of ESdM after 
transplantation. Thus, the beneficial effect of exogenously applied ESdM was very 
restricted to the local area where cells were transplanted. However, further 
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investigations on microglia and their application in APP transgenic mice could provide 
a novel approach for AD therapy. 
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5 Summary 
The role of microglia in Alzheimer’s disease (AD) is controversial, as it remains unclear 
if the microglia form the amyloid fibrils or react to them in a phagocytic role. However, 
there has been recognition that microglia may also play a neuroprotective role through 
phagocytosis of A!. To study microglial function, primary microglia are typically 
derived from mixed glial cultures from early postnatal brain tissue. Isolation of such 
primary microglia is time consumable and inefficient due to low cell yield. To 
overcome these limitations we established a reproducible procedure to differentiate 
mouse ES cells into the desired microglial cells.  
In this work, two distinct ES cell lines were differentiated into microglial precursor cells 
by a method allowing differentiation of embryoid bodies to microglia within a mixed 
brain culture. Several independent microglial precursor (ESdM) lines were generated 
from the ES cells and characterized by flow cytometry, immunocytochemistry and 
functional assays. All ESdM showed expression of IBa1, CD11b, CD45, F4/80, $4 
integrin and !1 integrin, but were negative for cKit and CD34. Furthermore, stimulation 
with interferon-# (IFN#) or lipopolysaccharides (LPS) demonstrated up-regulation of 
pro-inflammatory mediator gene transcription including nitric oxide synthase-2 (iNOS), 
interleukin-1! (IL1!) and tumor necrosis factor-$ (TNF$) at levels comparable to 
primary microglia. ESdM showed efficient and rapid phagocytosis of amyloid-! (A!) 
peptide, which was increased after stimulation with LPS. ESdM expressed the 
chemokine receptor CX3CR1 and demonstrated concentration dependent migration 
towards its ligand CX3CL1. After in vivo transplantation into postnatal brain tissue 
ESdM showed engraftment as cells with a microglial phenotype and morphology.  
The therapeutic application of ESdM was assessed in an animal model of AD (APP23). 
To overexpress GFP, ESdM were lentivirally transduced and locally injected to the 
cortex of APP23 mice. Immunohistochemistry showed that ESdM were able to 
contribute beneficially to a clearance of A! at the transplantation site resulting in a 
significant decreased total plaque area as well as in smaller plaques.  
In summary, ESdM are stable proliferating cells substantially having most 
characteristics of primary microglia and therefore being a suitable tool to study 
microglial function and to use them as a source for cell therapy applications. 
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